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Prof Catherine Comiskey, 
Amy Blake (Acting CEO Coolmine 
Therapeutic Community), 
Minister for Health Leo 
Varadkar and Alan Connolly 
(Chairman Coolmine Therapeutic 
Community) attending the launch 
of Coolmine’s longitudinal 
outcomes study 
On 25 January 2016 Coolmine Therapeutic 
Community (CTC) published the results of a 
longitudinal outcomes study Pathways through 
treatment: a mixed-methods longitudinal 
outcomes study of Coolmine Therapeutic 
Community.1 The key finding of the study is 
that, despite the many instances of relapse, 
the positive impact of all CTC programmes 
on clients is undeniable. 
Overall, substance use declined, physical and mental 
health improved, and clients demonstrated improvements 
with regard to housing, employment, education and 
family relationships.
The newsletter of 
Ireland’s focal point 
to the EMCDDA
Pathways 
through treatment
In brief
Tackling the harm caused to individuals 
and society by the misuse of drugs is the 
overall objective of the national drugs 
Strategy. Preventing drug-related deaths is 
the most obvious and pressing part of the 
work guided by this objective. The eMCdda 
estimates that there were at least 6,800 
overdose deaths in the european Union in 
2014. Opioid users, particularly those who 
inject drugs, are at particular risk. The 
growing number of deaths among older 
drug users reflects the ageing nature 
of the opioid-using population. 
This issue of Drugnet Ireland looks at several recent 
Irish and international studies which examine both the 
factors contributing to death among heroin users and 
the measures being taken to reduce the risk of death. 
Participation in opiate substitution treatment (OST) 
is known to reduce mortality among this group of 
drug users, particularly among those who inject. Risks 
remain, of course, for those in OST such methadone 
maintenance treatment. One of the studies looked at 
in this issue identified a significant association between 
risk of mortality and imprisonment, medical issues and 
engagement with treatment. The association between 
engagement in treatment and risk of death, from both 
poisoning and non-poisoning causes, is the specific focus 
of another study described in this issue, whose findings 
strengthen the evidence on the dangers of leaving OST. 
Drug-related deaths data also provide information 
about the circumstances in which a person dies, and 
the knowledge that a large number of those who die 
from an overdose are not alone at the time of death 
suggests that some of these deaths may be avoidable. 
It is known that naloxone can reverse respiratory 
depression and a recent EMCDDA study covered later 
in this issue synthesises recent evidence around the 
efficacy of take-home naloxone.
These studies demonstrate how innovative use of data 
gathered through routine monitoring, together with data 
held in prescription and other medical recording systems, 
can provide valuable insights into both the factors 
contributing to mortality and the means to prevent it. 
Contents
CovER StoRy 
Pathways through treatment 1
SPECIAl thEmE 
MeThadOne MaInTenanCe TreaTMenT 
Risk factors for death among MMT patients 5  
On and off methadone substitution treatment:  
risks of mortality 6
POlICy and legISlaTIOn
Next National Drugs Strategy under development 8
What’s in a drugs strategy? 10
Help not Harm symposium 12
Terminology and information on drugs  13
PrevalenCe and CUrrenT SITUaTIOn
Health in Ireland: key trends 2015 13
Misuse and dependence on 
codeine-containing medicines 16
The internet and drug markets 17
The drugs market and intimidation 19
reSPOnSeS
17th annual Service of Commemoration and Hope 21
A community partnership for tackling hepatitis C 22
Take-home naloxone  22
ServICeS
HRB National Drugs Library 24
Coolmine launches new strategy, 2016–2018 25
HSE national service plan 2016 26
TUSLA priorities for 2016 28
UPdaTeS
Recent publications 30
3
Issue 57 | Spring 20
16
      drugnet IR
ELAN
D
      
Self-discharges were highest among residential women 
(53.3%, n=16), next highest among clients of the DFDP 
(44.4%, n=8), and noticeably lower among male residential 
clients (21.2%, n=11). However, discharge owing to violation  
of a CTC protocol was highest among residential men 
(28.8%, n=15). 
The authors comment that it is not clear to what extent 
women discharged early owing to the apparent lack of 
community cohesion and general incompatibility with 
key treatment elements in Ashleigh House (see below 
under Quality of Life), or owing to their own personal 
circumstances such as family obligations or psychological 
needs. The authors suggest these factors were in all 
likelihood interdependent. 
The authors highlight how the circumstances surrounding an 
individual’s entry into treatment influenced the treatment 
outcome – whether the entry was ‘self-motivated’ (the client 
decided individually and autonomously to enter treatment), 
‘incentivised’ (the client entered following a negotiated, 
suspended prison sentence), or a combination of the two 
(the client was self-motivated to achieve abstinence but also 
faced tangible external pressure to comply with treatment). 
Those who had expressed high levels of self-motivation 
from the outset were more engaged with the therapeutic 
programme than those who entered out of a sense of 
obligation or pressure (i.e. incentivised clients), and this 
disparity became more apparent as time went on. 
The authors also report that motivation was noticeably 
stronger among clients on the drug-free day programme 
than clients on the residential programmes. Clients on 
the day programme reported entering after completing a 
separate residential programme; they were thus entering 
treatment after a period of sobriety and with previously 
acquired knowledge of treatment programmes. In addition, 
as the day programme was an optional extra after the 
residential programme, these clients tended to be highly 
committed to actively practising recovery. 
The primary aim was to track CTC clients over two years, 
gathering data on treatment retention, substance use, 
physical and psychosocial health, social functioning and 
criminal activity. The study also aimed to compare outcomes 
for clients of CTC’s three treatment programmes – male 
residential (the Lodge), female residential (Ashleigh House) 
and the mixed-gender drug-free day programme (DFDP). 
method
The mixed-methods study included quantitative information 
on 144 participants, and 86 qualitative interviews with 
28 participants, which allowed for in-depth exploration 
of issues.
Quantitative data collection commenced in February 2011 
with interviews taking place at baseline and at six-monthly 
intervals over the next two years. At baseline, the 144 
participants recruited to the study were entering a primary 
treatment service at Coolmine Therapeutic Community. 
Qualitative interviews also took place at six-monthly 
intervals, starting in March 2011 and continuing for two years. 
Qualitative data were collected from voluntary participants 
ranging in age from 20 to 47 years through semi-structured 
interviews at six-monthly intervals. The average of those in 
this sample was 32 years. CTC’s three primary treatment 
programmes were almost equally represented in this sample, 
16 (58%) of whom were male and 12 (42%) female. While 86% 
of participants reported opiates as their primary problem 
drug, poly-drug use was common.
Findings
The study found an improvement in nearly all measured 
outcome areas over the two years of the study. Some 
programme-based and gender-based differences 
in treatment pathways, experiences and outcomes 
were uncovered. 
treatment retention, substance use and outcomes 
At treatment intake all 144 participants were actively 
engaged in one of CTC’s three programmes. At the final 
24-month data collection phase, 77.1 per cent (n=111) were 
retained in the study, and of these, 72 per cent (n=80) were 
reported to be drug-free. Thirty-six per cent of this final 
sample (n=40) had graduated from their programmes, 
and 85% (n=34) of these reported being drug-free at 24 
months. In other words, the number of clients reporting 
drug-free status was approximately double that of those 
who graduated.
The proportion of participants who reported using illicit drug 
use in the 30 days preceding data collection fell from 43.1 
per cent at baseline, to 35.5 per cent at one year and 27.9 
per cent at two years. This relapse rate was relatively low 
compared to rates reported in a recent (2013) systematic 
review of therapeutic communities (25%–55%).
Graduation rates varied by programme – from 26.7% (n=8) 
for female residential clients (Ashleigh House), to 36.5% 
(n=19) for male residential clients (The Lodge), to 50% (n=9) 
among those on the drug-free day programme (DFDP). 
Minister Leo Varadkar and Mr Alan Connolly (Chairman 
Coolmine Therapeutic Community) at the launch of 
Coolmine’s longitudinal outcomes study
Pathways to treatment  continued
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16 Qualitative data revealed that the main difficulty in 
finding paid employment was a lack of formal education 
qualifications, leading many participants to consider 
returning to education. Because maintaining abstinence 
was viewed as the most immediate and important goal, a 
considerable number of participants expressed a preference 
for employment that was not overly demanding stress-
inducing. Some participants reported being unable to 
secure employment owing to their past criminal activity.
Criminal activity
Qualitative data revealed that most participants had a 
background involving some level of criminal activity, much 
of it associated with supporting a lifestyle largely focused 
on drug acquisition and use. This was particularly the case 
for male participants. The proportion of participants who 
reported committing a criminal act in the 30 days preceding 
data collection fell from 8.6 per cent at baseline to 1.8 per 
cent at two years. 
Conclusions
Despite the many instances of relapse, the authors conclude 
that the positive impact of all CTC programmes on clients 
is undeniable. Overall, substance use declined, physical 
and mental health improved, and clients demonstrated 
improvements with regard to housing, employment, 
education and family relationships. Many clients cited the 
tools they had acquired in treatment as key mechanisms 
for continued change. Some participants suggested ways 
in which CTC services could be improved and the authors 
suggest these ‘key messages’ could be applicable not only 
to CTC but to drug and alcohol therapeutic communities 
more generally:
• flexibility in delivery of programmes, e.g. scheduling, 
structure, treatment timeline, multiple programming 
options;
• additional one-to-one support;
• smaller group sessions;
• more support for residential clients moving from 
residential treatment into community housing with peers;
• day programme as step-down after completing a 
residential programme; and 
• motivation enhancement.
Anne marie Carew, Brigid Pike and Brian Galvin
1. Babineau K and Harris A (2016) Pathways through treatment: 
a mixed-methods longitudinal outcomes study of Coolmine 
therapeutic community Dublin: Coolmine Therapeutic 
Community. http://www.drugsandalcohol.ie/25091/
Physical health and psychological health
Although women’s physical health, mental health and 
self-reported well-being were all lower than men’s on 
entry to treatment, the mean physical health scores of 
both increased (males: 11.62 at baseline to 14.49 at two 
years; females: 10.28 at baseline to 13.05 at two years), 
as did the mean psychological health scores of both 
(males: 11.43 at baseline to 12.97 at two years; females: 
9.6 at baseline to 13.18 at two years). 
The participant interviews reflected the quantitative findings. 
While many reported on-going health problems, including 
serious and chronic co-morbidities such as HIV and hepatitis 
C, most who remained drug-free in their final interview 
reported that their physical health was markedly improved. 
Positive mental health was often reported as having to be 
actively maintained, e.g. through participating in fellowship 
meetings or adhering to a structured daily routine. Female 
participants were more likely than males to report mental 
health issues, such as periods of depression, anxiety, 
self-harm, suicide ideation and suicide attempts.
Quality of life
The mean quality of life score showed a similar upward trend 
for both men and women (males: 11.62 at baseline to 13.91 at 
two years, females: 10.29 at baseline to 13.36 at two years). 
Improvement in overall quality of life was also reflected in 
the qualitative data. However, while engaged with CTC, men 
and women seem to have responded differently to some 
elements of the therapeutic programme. 
Broadly speaking, men responded positively to group living, 
including the communal residential spaces, the shared 
chores, and the group therapy. Several of the women, 
however, struggled with the group element of residential 
treatment including the group chores and group sessions. 
Some of the women who had their children with them in 
Ashleigh House reported that they felt detached from the 
group-treatment experience, particularly unstructured 
group time, when compared to those who did not have 
children in residence with them, as they struggled to 
balance parenting and participation. 
housing
The proportion of participants reporting acute housing 
difficulties rose from 21.7 per cent at baseline to 22.8 per 
cent at two years. According to the authors, this increase 
may have been related to the fact that many clients at intake 
were engaged in CTC or another formal treatment service 
and were not experiencing acute housing problems. The 
majority of participants who were interviewed reported 
relying on housing services for assistance in securing housing 
and many found clean, safe and comfortable places to 
reside. But for some, owing to prior periods of homelessness 
and incarceration, the experience was challenging and far 
more precarious. 
Education and employment 
Both male and female clients were distinctly more active 
in their attempts to engage with education and the labour 
market after engaging with CTC. The proportion engaged 
in paid employment increased from 3.5 per cent at intake 
to 25 per cent at two years, and the proportion enrolled 
in education increased from 1.4 per cent to 17 per cent. 
Pathways to treatment  continued
5
Issue 57 | Spring 20
16
      drugnet IR
ELAN
D
      
The logistic regression model reinforced these results with 
the significant variables found to be history of imprisonment, 
non-attendance at the NDTC one week prior to death, and a 
non HIV/HCV medical condition. HIV status was not found to 
be significantly associated with risk of death using this model.
Poisoning deaths 
The authors attempted to delineate between poisoning 
deaths and other types of deaths, in an attempt to 
determine if there were different risk factors for deaths in 
these cases. Poisoning deaths included all drug overdoses 
(intentional or accidental). Other causes of death included 
trauma (murder, road traffic accident, etc) and medical 
causes (infection, organ failure, etc). Cause of death was 
possible to determine in 77 out of 80 cases; no suicides 
were recorded, though the authors noted that this might 
possibly have been under-recorded owing to some coroners 
recording suicides as ‘accident/misadventure’. 
Records showed that 33 out of the 80 patients had died of 
poisoning. The only significant statistical difference between 
this cohort and cases who did not die of poisoning was a 
slightly younger average age (34.2 versus 41.3, p<0.001). 
Comparing the poisoning cases with their controls, similar 
significant associations were found (HIV positive, not 
attending the NDTC for at least one week prior to death, 
history of imprisonment, non-HIV/HCV medical problems). 
The poisoning deaths cohort was also found to have been 
more likely to have a history of homelessness (p=0.03). 
Discussion
The authors noted that other studies had shown that 
increased risk of mortality had been associated with low 
or very high doses of methadone. No such association was 
witnessed in this study. Similarly, previous studies had shown 
an increased risk of mortality among MMT patients with 
problem cocaine use, but this study showed no significant 
associations between ongoing problem drug use and risk of 
mortality.
Three significant associations were identified, however, in 
relation to imprisonment, medical issues and attendance at 
the NDTC for MMT.
• Other studies have pointed to the risk of lower tolerance 
on release from prison being a cause of overdose. 
The authors of this paper chose to focus on history of 
imprisonment, and showed that the cases were more 
likely than the controls to have a history of imprisonment. 
They theorised that being imprisoned could be linked to 
prisoners being one of the most disadvantaged groups in 
society, and noted that previous studies had shown an 
elevated risk of mortality among ex-prisoners. 
• Recent studies have shown that HIV patients who were 
injecting drug users (IDUs) have a mortality rate 20 
times higher than non-IDU patients. This study showed 
that there were significantly more HIV patients among 
the case group than the control group. The study also 
showed a link between non-HIV/HCV medical illness 
and mortality, as one would expect. Interestingly, among 
the cases who died of poisoning, medical issues were 
significantly more common in comparison to controls. 
The authors suggested that this might be linked to 
‘increased susceptibility to the respiratory depressant 
effect of opioids among the medically unwell’. The 
authors suggested that prevention, and early detection 
and treatment, may help reduce mortality.
SPECIAl thEmE: 
METHADONE MAINTENANCE TREATMENT 
Risk factors for 
death among 
mmt patients
International studies have shown that problem alcohol or 
drug users have increased mortality rates in comparison to 
the general population. Mortality rates are further elevated 
among individuals with serious opiate addictions, and 
especially among injecting drug users (IDUs). Methadone 
maintenance treatment (MMT) is shown to reduce the 
mortality rate for this cohort of problem drug users, but in 
comparison to the general population MMT patients still have 
a higher risk of mortality.
The aim of this study1 was to explore what risk factors might 
contribute to increased mortality among MMT patients. The 
authors stated that they were specifically interested in the 
hypothesis that methadone dosage and problem use of non-
opiate drugs might be associated with an increased risk of 
mortality. They were also interested in whether there were 
different risk factors among cases who died from poisoning 
and cases who died from other causes.
The authors used a matched case-control study. They 
examined treatment exit records from the National Drug 
Treatment Centre (NDTC) in Dublin for seven years from 
February 2005 to February 2012. They identified all patients 
whose treatment outcome was recorded as death. Cause 
of death for these cases was determined using information 
from the National Drug-Related Deaths Index (NDRDI). 
Controls for the study were MMT patients who had not died, 
and matching was done by age, gender and treating team. 
The authors conducted two separate statistical analyses. 
Uni-variable associations between risk of death and age, 
gender, methadone dose, non-attendance at treatment 
for at least one week prior to death, drug use in the month 
preceding death, history of imprisonment, HIV status, and 
medical complications were examined. For the controls, an 
index date, equal to the date of death, was created, and this 
was used to analyse the same set of death-related variables. 
A second analysis was conducted using binary logistic 
regression with alive/dead as the outcome variable. 
Results
Over the seven years of the study the average number of 
MMT patients at the NDTC was 500, and 80 deaths were 
recorded over the same period. No statistical difference  
in methadone dosage was found between cases and controls 
and neither was there a significant difference in recent  
use of heroin, benzodiazepines or cocaine. Cases were  
more likely to have a history of imprisonment (p<0.001);  
not attended the NDTC for at least one week prior to death 
(p<0.001); HIV (p=0.01); non-HIV/HCV medical problems 
(p<0.001); and more frequent medical/psychiatric reviews 
(p=0.03).
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16 absent for a short period of time. A pro-active approach, 
the authors suggested, could help reduce the increased 
risk of mortality faced by those who disengage.
martin Grehan
1. Truszkowska E, McCarron P, Konovalov P, Galander T, Lyons 
S, Keenan E and Smyth BP ( (2015) Case-control study of risks 
and causes of death amongst opioid dependent patients on 
methadone maintenance treatment. The Canadian Journal of 
Addiction 6 (3): 17–25. http://www.drugsandalcohol.ie/25004/
• Other studies have shown an increased risk of mortality 
among patients who have disengaged from MMT, and 
especially in the first weeks out of treatment. This study 
observed that a significant minority of cases had been 
disengaged from treatment at time of death. The authors 
recommended educating MMT-patients on the increased 
risk of overdose if they ceased treatment, and that clinics 
should follow up on patients, even if they have only been 
on and off 
methadone 
substitution 
treatment: risks 
of mortality
A recently published study aimed to assess the risk of  
death when initiating or stopping methadone treatment  
in primary care.1 In addition, the study looked to assess  
the effect of supervised methadone consumption on 
mortality rates.
Data from the Central Treatment List (CTL) were used to 
identify cases that were in receipt of at least one methadone 
prescription in primary care over the six years between 
August 2004 and December 2010. The CTL data were 
linked to the Methadone Treatment Scheme (MTS) 
dispensing records. These were further linked to the General 
Medical Services (GMS), which contains information on 
all other prescription medication, excluding methadone. 
Finally, these were linked to the mortality data recorded 
by the National Drug-Related Deaths Index (NDRDI). A case 
was considered ‘off treatment’ if the individual had not 
received a new methadone prescription for three days since 
the end of their last prescription. They were considered ‘off 
treatment’ until a new prescription was generated.
The main outcome measure was drug-related mortality, 
defined as a death due to poisoning as per the NDRDI 
definition. The second outcome measure was all-cause 
mortality. 
Table 1: Characteristics of people (alive and dead) receiving methadone treatment, Ireland, August 2004 – December 2010
 Total
n=6983
Alive
n=6770
Dead
n=213
% % %
Male 68.7 65.8 74.2
Age (years)
16 to 19 7.5 7.7 0.9
20 to 29 50.4 51.0 31.5
30 to 39 31.8 31.6 39.0
40 to 65 10.3 9.7 28.6
Number of treatment episodes
≤4 46.2 46.0 53.1 
≥ 5 53.8 54.0 46.9
Median length of treatment episode (days) 83 85 60
Median dose last treatment episode
<60mg 38.0 38.2 29.6 
60 to 120 mg 59.6 59.3 67.6
≥120 mg 2.5 2.5 2.8
Supervised methadone consumption
≥50% prescriptions supervised 40.4 40.9 26.8
<50% prescriptions supervised 59.6 59.1 73.2
Co-prescribing 71.2 71.0 78.4
Benzodiazepines 22.8 22.6 28.6
Antipsychotics 48.0 48.0 47.4
Opioid analgesics 39.5 39.4 41.8
Source: Adapted from Cousins et al (2015)
MMT– mortality risk  continued
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to four (1.19 deaths per person years). Again, there was no 
statistical difference between the time periods or from 
those on treatment.
Analysis of all-cause mortality, adjusted for gender, age and 
comorbidity, showed that people who were off treatment 
were three times more likely to die than those on treatment 
(3.6, 95% CI 2.1 to 6.3) (Table 2). The risk of mortality was 
highest in the third and fourth week after stopping treatment 
(9.1, 95% CI 3.1 to 26.2). However, the risk of mortality off 
treatment after five weeks or more remained higher than 
being on treatment. A higher risk of dying was associated 
with age and increased co-morbidity, as shown by the 
median co-morbidity score. The authors noted that in the 
unadjusted analysis, mortality was higher among those 
whose methadone consumption was not supervised (1.36, 
95% CI 1.00 to 1.84) but this was not found to be statistically 
significant in the adjusted analysis.
One of the potential limitations of the study was the 
definition of ‘off treatment’ as not receiving a methadone 
prescription for three days since the end of the last 
prescription. This cut-off was based on UK guidelines which 
are based on reduction of tolerance. However, a sensitivity 
In total, 6,983 cases aged between 16 and 65 years who 
received methadone were included in the study. Of these, 
the majority were male (69%) and 57 per cent were aged 
29 years or younger (Table 1). The majority of cases had 
received methadone treatment five or more times, with a 
treatment period lasting a median of 83 days. Three per 
cent (n=213) of those included in the study died during the 
study period. 
Of the 213 people who died, 98 (46.0%) were classified as 
being off methadone treatment. The deaths of over a third 
(78, 37%) were classified as being due to poisoning. Opiates 
(n=72) and benzodiazepines (n=56) were the drugs most 
frequently reported in the toxicology reports on these cases. 
The risk of dying because of poisoning was highest when a 
person was off treatment (0.39 deaths per person years) 
compared to on treatment (0.24 per person years) but this 
was not statistically significant. For those off treatment, 
mortality rates from poisoning were highest in weeks one 
to two (0.49 deaths per person years) and in weeks three 
Table 2: All-cause mortality among people receiving methadone treatment, Ireland, August 2004 – December 2010
Adjusted analysis
 Number of 
Deaths
Mortality/100 
person-years
Mortality rate ratio
(95% CI)
P-value
Overall on treatment 115 0.51 1.00 <0.001
Overall off treatment 98 1.57 3.64 (2.11 to 6.30)
Period
Weeks 1 to 2 on treatment 9 0.49 0.88 (0.23 to 3.33) <0.001
Weeks 3 to 4 on treatment 6 0.39 0.71 (0.14 to 3.51)
Remainder of time on treatment 100 0.52 1.00
Weeks 1 to 2 off treatment 29 3.46 6.36 (2.84 to 14.22)
Weeks 3 to 4 off treatment 15 4.38 9.12 (3.17 to 26.28)
Remainder of time off treatment 54 1.07 2.46 (1.28 to 4.37)
Sex
Female 55 0.59 1.00 0.2
Male 158 0.81 1.54 (0.81 to 2.90)
Age (years)
16 to 19 2 0.16 1.00 0.006
20 to 29 67 0.47 3.18 (1.21 to 49.20)
30 to 39 83 0.83 5.62 (1.36 to 86.82)
40 to 65 61 1.87 10.40 (4.66 to 164.52)
Supervised consumption
Yes 57 0.60 1.00 0.500
No 156 0.81 1.23 (0.67 to 2.27)
Median comorbidity score*
0 to 5 130 0.58 1.00 0.007
6 to 10 52 0.95 1.65 (0.87 to 3.13)
11 to 15 23 2.65 4.66 (1.88 to 11.50)
> 16 8 5.06 6.06 (1.46 to 25.18)
Source: Adapted from Cousins et al (2015)
* Measured by number of prescriptions for benzodiazepines, antipsychotics, antidepressants and opiates (excluding methadone) received by participant in 
a calendar year
On and off MMT– 
mortality risk  continued
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16 Editorial comment
In response to this newly-published Irish study on the risks 
of mortality on and off methadone substitution treatment in 
primary care, Professors Matthew Hickman, John MacLeod 
and Louisa Degenhardt wrote an editorial in the journal 
Addiction, stating: 2
The National Irish cohort study strengthens evidence 
on the hazards of leaving opioid substitution 
treatment (OST) and the dangers of short duration 
treatment and provides the first piece of evidence 
for future synthesis of the effect of supervised 
consumption on mortality risk in people on OST.
In their commentary, they stressed the need for robust and 
reliable evidence to enable service providers to provide the 
best possible drug treatment in order to reduce mortality in 
this vulnerable cohort of people. This evidence is particularly 
pertinent when wanting to understand if changes in drug 
treatment have had any impact on mortality or outcomes. 
The professors also noted that this Irish study had provided 
some weak evidence suggesting that supervised consumption 
may reduce the risk of mortality but further evidence is 
needed to build on this finding. 
Suzi lyons
1. Cousins G, Boland F, Courtney B, Barry J, Lyons S and Fahey 
T (2015) Risk of mortality on and off methadone substitution 
treatment in primary care: a national cohort study. Addiction 111 
(1): 73-82. http://www.drugsandalcohol.ie/24374/ 
2. Hickman M, Macleod J and Degenhardt L (2016) Commentary on 
Cousins et al (2016): Accumulating evidence on risk of mortality 
on and off opioid substitution treatment. Addiction (111): 83–84. 
analysis extending the cut-off to seven days also showed 
increased mortality off treatment, (3.06 95% CI 1.74 to 5.39). 
Another limitation was that people transferring from primary 
care to specialist methadone clinics were not included and 
so were classified as ‘off treatment’. These limitations were 
compounded by the lack of information on those who were 
off treatment, for example they may have been in prison, 
stopped their opiate use or been hospitalised. 
While acknowledging the strengths of the study, such as 
the large national cohort of people receiving methadone 
who were included and the detailed prescription data 
from primary care, the inability to control for the residual 
confounders noted above is often a problem in such 
observational studies and the findings from this study should 
be viewed as a basis for further research. In particular, 
the authors recommended further research in relation 
to supervised consumption.
The findings also have implications for national practice and 
policy as they show that retention in treatment in primary 
care is associated with a reduced risk of all-cause mortality. 
The authors also recommended that when a person leaves 
methadone treatment in primary care there should be 
improved post-treatment monitoring and follow-up for the 
first month, when relapse rates are highest along with the 
greatest risk of dying. 
 
POLICY AND LEGISLATION 
Next National Drugs 
Strategy under 
development
The Cabinet Committee on Social Policy and Public Service 
Reform has mandated the Department of Health to develop 
a new National Drugs Strategy, to follow the current National 
Drugs Strategy which will expire at the end of 2016.1 Late 
in 2015 the Minister with responsibility for the National 
Drugs Strategy established a Steering Committee to provide 
him with guidance and advice in the development of the 
new Strategy. This Committee met for the first time on 8 
December 2015.
Steering committee
The Steering Committee is tasked with considering how the 
new Strategy should address problem drug use, including the 
structures through which this could be done, and developing 
performance indicators to measure the effectiveness of the 
new Strategy. It will present a draft report to the Oversight 
Forum on Drugs for discussion and amendment, and then 
submission to the Minister with responsibility for the National 
Drugs Strategy, who will submit the proposed new Strategy 
to the Cabinet Committee on Social Policy and Public Service 
Reform for approval. The new Strategy is expected to be 
finalised by the end of 2016.
The Steering Committee has a comprehensive and wide 
ranging membership, representing the key government 
departments and agencies responsible for implementing 
the Strategy as well as the community and voluntary sectors 
and the drugs and alcohol task forces. John Carr, a former 
general secretary of the Irish National Teachers Organisation, 
is the independent chair of the Steering Committee.
The work of the Steering Committee will be informed by 
the following inputs, delivered over the first half of 2016 
– a report from an international expert review group, an 
evidence briefing compiled by an independent academic 
institution, and feedback from focus groups. 
International expert review group
During a week-long visit to Ireland in January 2016, a group 
of three international experts undertook a high-level review 
of the current National Drugs Strategy, and reported to the 
Steering Group on their findings and observations. 
On and off MMT– 
mortality risk  continued
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The Cabinet Committee has stipulated that there should be 
a fundamental review of all aspects of the current National 
Drugs Strategy, including the role of the drugs and alcohol 
task forces. Issues that the Steering Committee has been 
particularly asked to consider are: 
• the length of the Strategy, and whether to develop a 
more concise and focused version, to facilitate clear and 
concise reporting on progress and implementation;
• the optimum duration of the Strategy in order to reflect 
the changing nature of the drugs phenomenon and the 
need to maintain the momentum necessary to keep pace 
with changing drug trends;
• the five pillars and whether new or alternative pillars are 
needed to ensure that the Strategy is focused on new or 
emerging issues; and
• the appropriate balance between the objectives of 
supply reduction and demand reduction.
this report is based on information provided by the Drug 
Policy Unit in the Department of health in December 2015.
1. Department of Community, Rural and Gaeltacht Affairs 
(2009) National Drugs Strategy (interim) 2009–2016. Dublin: 
Department of Community, Rural and Gaeltacht Affairs. http://
www.drugsandalcohol.ie/12388/
2. Office for Social Inclusion (2007) National action plan for social 
inclusion 2007–2016. Dublin: Stationery Office. http://www.
drugsandalcohol.ie/13378/
3. Department of Health (2013) Healthy Ireland – a framework for 
improved health and wellbeing 2013–2025. Dublin: Department 
of Health. http://www.drugsandalcohol.ie/19628/
4. Council of the European Union (2012) The EU drugs strategy 
2013–2020. Brussels: Council of the European Union. http://
www.drugsandalcohol.ie/19034/ 
5. Council of the European Union (2013) EU action plan on drugs 
(2013–2016). Brussels: Council of the European Union. http://
www.drugsandalcohol.ie/20004/ 
 
This expert review group included Paul Griffiths, Scientific 
Director with the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), who will chair the group; Nicola 
Singleton, also of the EMCDDA; and Professor John Strang of 
the National Addictions Centre, Kings College, London. The 
group’s terms of reference included examining the progress 
and impact of the current National Drugs Strategy in the 
context of the objectives, key performance indicators and 
actions set out in the Strategy; identifying deficits in the 
implementation of the Strategy; summarising success factors 
or barriers to success; commenting on Ireland’s evolution in 
tackling the drug problem in the light of international trends; 
and identifying key learning points arising from the Strategy 
and highlighting areas to consider for development in the 
new strategy. 
Independent evidence briefing 
During the first four months 2016 a two-part evidence 
briefing, compiled by researchers at Liverpool John Moores 
University, was presented to the Steering Committee. It 
comprises (1) a report on the drugs situation in Ireland, 
including a ten-year trend analysis, and (2) an overview of 
international evidence on interventions in the following 
response areas – prevention (universal, selective and 
indicated), harm reduction, treatment (medical, 
psychosocial and residential modalities, and social 
reintegration (rehabilitation and recovery). 
Focus groups 
To enable engagement with statutory, community and 
voluntary bodies who have a role in the delivery of the 
objectives of the Strategy, the Steering Committee will 
establish four focus groups to consider the following topics:
• Supply reduction
• Education and prevention 
• Continuum of care (encompassing treatment, 
rehabilitation and recovery) 
• Evidence and best practice
Chaired by the Chair of the Steering Committee, these focus 
groups will meet in the first months of 2016 and give their 
views on the relevance of the current Strategy in tackling 
problem drug use in Ireland, identify any gaps presenting and 
indicate how they believe these gaps might be addressed. 
It is envisaged that the new Strategy will take account of 
national policy frameworks such as the National Action Plan 
for Social Inclusion 2007–20162 and the Healthy Ireland 
Framework3 as well as international policies, such as the EU 
Drugs Strategy 2013–20204 and the associated Action Plan,5 
which is supported by Ireland. 
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Traditionally, ‘balanced’ drugs strategies have been built 
around the twin aspirations of reducing supply and demand, 
with actions grouped under themes such as enforcement, 
prevention, treatment and rehabilitation. The UK Drug Policy 
Commission, an independent charity that sought to provide 
objective analysis of the evidence concerning drug policies 
and practice, suggested that attention should shift at the 
strategic level from focusing on ‘inputs’ to looking at the 
desired outcomes:
We suggest making a clear distinction between the 
overall goals of drug policy and the tools to deliver it. 
Rather than starting with the traditional distinction 
between prevention, treatment and enforcement, 
it may be more effective to consider drug policy in 
terms of two higher level challenges (p. 11).2 
These two higher-level challenges were characterised 
as follows:
1. How can society and government enable and support 
individuals to behave responsibly, i.e. tackle the 
underlying causes of drug use, providing the information 
and skills to make sensible choices, and, where drug 
use does occur, minimise the associated harms?
2. How can society and government enable and promote 
recovery from entrenched drug problems, be it 
individuals or communities?
Another way of shifting the focus on to outcomes has been 
tried by New Zealand and Scotland, who have set their 
national drugs strategies within the framework of broader, 
over-arching public sector outcomes. In New Zealand, the 
thinking is that progress towards the twin drug policy goals 
of minimising harm and promoting and protecting the health 
and well-being of all New Zealanders will impact on four 
wider social sector outcomes:
• reducing welfare dependency,
• supporting vulnerable children,
• boosting skills and employment, and
• reducing crime.1
The current Scottish drug strategy, launched in 2008, 
is similarly located within the context of the Scottish 
government’s ‘overarching purpose, which is to increase 
sustainable growth’.3 This purpose is supported by a National 
Performance Framework, which cascades down through five 
strategic objectives (to make Scotland wealthier & fairer, 
smarter, healthier, safer & stronger, and greener) and 15 
national outcomes to 45 national indicators. One of the 45 
indicators is to ‘reduce the estimated number of problem 
drug users in Scotland by 2011’. The Minister wrote in his 
Foreword to the drug strategy, ‘Reducing problem drug use 
will get more people back to work; revitalise some of our 
most deprived communities; and allow significant public 
investment to be redirected’(p. iv). 
What’s in a 
drugs strategy?
While work is proceeding on developing the strategic 
approach that will be adopted when the current National 
Drugs Strategy 2009–2016 expires at the end of this year, 
Drugnet Ireland takes a look at a selection of current drugs 
strategies from around the world to explore the range of 
approaches that are being taken to this complex and 
hydra-headed challenge.1 
Coverage
Many countries have extended the range of their strategies 
beyond illicit substances to include licit substances. 
Australia Alcohol, tobacco, cannabis, 
 methamphetamines and other stimulants,  
 new psychoactive substances, opioids, 
 and misused pharmaceuticals
Cyprus Drugs and harmful use of alcohol
New Zealand Alcohol and other drugs
Norway Alcohol, illicit drugs, addictive 
 medications and doping
Spain Addictive substances, whether they 
 be those that are legally traded, such 
 as alcohol, tobacco and certain 
 pharmaceutical drugs, or those 
 excluded from legality
Sweden Alcohol, narcotic drugs, doping 
 and tobacco
United Kingdom Illicit drugs and alcohol dependence
United States Controlled drugs including prescription 
 drugs, alcohol and tobacco 
Four countries in the EU have extended their strategic 
reach further, to include addictive behaviours as well 
as substances. 
Czech Republic Illicit drugs, alcohol and gambling
Croatia Illicit drugs, precursors and new 
 psychoactive substances and doping, 
 licit drugs (alcohol, tobacco, prescription 
 medications), and other addictions 
 (gambling, the Internet)
France Illicit drug use, alcohol, tobacco, 
 psychotropic medications and other 
 addictive behaviours such as doping, 
 gambling and gaming
Germany  Addictive substances and behaviours, 
including alcohol, tobacco, prescription 
drug addiction and prescription drug 
abuse, pathological gambling, online 
media addiction and illegal drugs.
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the principles of shared responsibility, a long-term 
perspective and increased coordination and cooperation, 
the strategy calls for ‘a comprehensive, integrated 
approach focused on the individual/user and the family’.
• United Kingdom: The current strategy shifts the focus 
from harm reduction to recovery. Holistic solutions are to 
be centred around each individual, with the expectation 
that full recovery is possible and desirable. The option of 
decriminalisation is rejected as failing to have regard to 
the harms that drugs pose to the individual: ‘It neither 
addresses the risk factors which lead individuals to 
misuse drugs or alcohol, nor the misery, cost and lost 
opportunities that dependence causes individuals, their 
families and the wider community (p. 2).’
Brigid Pike
1. Commentary and documents relating to EU member states with 
current national drugs strategies, and also Norway and Turkey, 
were retrieved from the web site of the European Monitoring 
Centre for Drugs and Drug Addiction http://www.emcdda.
europa.eu/countries. Only strategies written in or translated into 
English, and current in 2016, have been considered. Information 
on the national drugs strategies of selected non-EU countries 
were retrieved from the following web sites: Australia: http://
www.nationaldrugstrategy.gov.au/; New Zealand: http://www.
health.govt.nz/publication/national-drug-policy-2015-2020 ; 
United States: https://www.whitehouse.gov/ondcp/national-
drug-control-strategy 
2. UK Drug Policy Commission (2012) A fresh approach to drugs: 
the final report of the UKDPC. London: UKDPC. http://www.
ukdpc.org.uk/wp-content/uploads/a-fresh-approach-to-drugs-
the-final-report-of-the-uk-drug-policy-commission.pdf 
3. Scottish Government (2008) The road to recovery: a new 
approach to tackling Scotland’s drug problem Edinburgh: 
The Scottish Government. http://www.gov.scot/
Publications/2008/05/22161610/0 
4. Preamble to the European Charter of Fundamental Rights, 
http://ec.europa.eu/justice/fundamental-rights/charter 
index_en.htm
Principles and values
National drug strategies that adopt a balanced, integrated 
approach, focusing on reducing both supply and demand 
(e.g. Croatia, Czech Republic, France, Germany, Slovakia, 
Slovenia and Spain), tend to include instrumental guiding 
principles, as does the Australian drugs strategy, which takes 
a harm-minimisation approach. These instrumental guiding 
principles include:
• long-term and comprehensive planning,
• realistic decision making – using evidence and 
evaluation of effectiveness,
• rational funding and service quality guarantee,
• partnership and common approach,
• professional cooperation at system interfaces 
and networks, 
• reaching people in a local context, 
• taking the most vulnerable, high-risk population 
groups into account in order to reduce health and 
social risks and negative impact, including a focus 
on gender sensibilities, and
• social participation as a way of raising awareness 
in society at large.
‘European values’, i.e. ‘human dignity, freedom, equality and 
solidarity … democracy and the rule of law’,4 are explicitly 
mentioned in the drugs strategies of several Eastern 
European countries (Croatia, Czech Republic, Slovakia and 
Slovenia). The Croatian and Slovenian drugs strategies also 
list human rights protection among their guiding principles. 
Compassion is highlighted in two national drugs strategies. 
In New Zealand, compassion is identified together with 
innovation and proportionality as an essential ingredient if 
alcohol and other drug problems are to be truly recognised 
as health issues. In his introduction to the 2015 US National 
Drug Control Strategy, President Obama wrote that his 
administration was pursuing a drug policy that is ‘effective, 
compassionate and just’. He went on to write about erasing 
the stigma of addiction, ensuring both treatment and a 
path to recovery, and reforming the criminal justice system 
to provide alternatives to incarceration for non-violent, 
substance-involved offenders and improving re-entry 
programmes. 
The need to focus on the individual and their families 
is highlighted in two national drugs strategies that have 
adopted a strong value-driven ambition to eradicate drug 
use from society:
• Sweden: The strategy’s overall objective – a society free 
from illegal drugs and doping, with reduced alcohol-
related medical and social harm, and reduced tobacco 
use – is based on a vision of a society where all may grow 
up, live and work without risking harm through their 
own use of alcohol, narcotic drugs, doping substances 
or tobacco, or through such use by others. As well as 
What’s in a drugs strategy?  continued
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Government efforts
Cormac O’Keefe of the Irish Examiner interviewed two 
TDs – Jonathan O’Brien of Sinn Féin and Aodhán Ó Ríordáin 
of the Labour Party. Both politicians spoke in favour of 
decriminalisation. They pointed out that various harm 
reduction measures, such as medically-supervised injecting 
centres and pill testing, entail some degree of decriminalised 
drug use.
What works?
Josie Smith, Head of Substance Misuse at Public Health 
Wales,5 described two public health programmes operating 
in Wales:
• WEDINOS – a national framework for the collection, 
analysis and dissemination of information relating to 
novel and/or unknown substances and combinations of 
substances, both psychoactive and performance/image 
enhancing drugs, to improve the provision of relevant 
harm reduction advice and service development.
• Harm Reduction Database Wales – a national web-based 
surveillance system to evidence effective interventions 
including needle and syringe programmes, take-home 
Naloxone, fatal and non-fatal drug poisoning reviews and 
sexual health.
Aisling Reidy, Senior Legal Advisor with Human Rights Watch,6 
described the work of Human Rights Watch based in New 
York. She noted that a range of UN bodies such as UNAIDS 
have called for a harm reduction approach to be adopted by 
the UN drug policy agencies.
Denis O’Driscoll, Chief II Pharmacist in HSE Addiction 
Services, spoke about the Naloxone Project which was 
launched in Ireland in May 2015.
Concluding discussion
In the concluding discussion, several themes were 
highlighted:
• Saving lives and reducing the harms of drugs 
are the priority.
• Drug policy needs to get out of the way of good 
social policy.
• A human rights approach to drug policy needs 
an evidence base.
Brigid Pike
1. For more information, visit http://www.helpnotharm.org/ 
2. For more information, visit https://www.pmvtrust.ie/ 
3. Retrieved 1 February 2016 http://www.iccl.ie/iccl-submission-
to-the-oireachtas-joint-committee-on-justice-defence--
equality-on-the-review-of-irelands-approach-to-possession-
of-limited-quantities-of-certain-drugs.html 
4. For more information, visit http://www.hr-dp.org/ 
5. For more information, visit http://www.wales.nhs.uk/
sitesplus/888/page/72997 
6. For more information, visit https://www.hrw.org/
help not harm 
symposium
On 28 January 2016 Help not Harm held a pre-election 
symposium in Dublin with contributors speaking on three 
themes – failures of the criminal justice approach and of 
government efforts, and exploring what works?1 
Failures of the criminal approach 
Catherine Comiskey, Head of School of Nursing and 
Midwifery, TCD, outlined how the growing body of 
research-based evidence shows that drug treatment 
‘works’ and strengthens the case for a stronger focus 
on respecting the human rights of drug users.
Peter McVerry, Executive Director of the Peter McVerry 
Trust,2 argued that, given that the ‘war on drugs’ has not 
worked and given that it has proved impossible to reduce 
the supply of drugs, it is important to focus on seeking 
to reduce demand. He called for greater investment in 
treatment options – to eliminate waiting lists and to expand 
residential and after-care service provision. He argued 
that this additional investment could be cost-neutral if 
decriminalisation were adopted as a policy at the same 
time: the savings in the criminal justice system could be 
channelled into drug treatment.
Mark Kelly, Executive Director of the Irish Council of Civil 
Liberties (ICCL), spoke about the submission that ICCL 
had made to the Joint Committee on Justice, Defence 
and Equality on the review of Ireland’s approach to the 
possession of limited quantities of certain drugs in August 
2015.3 In it the ICCL stated:
Human-rights-sensitive drug policy should be 
evidence- or science-based. While the state has a 
recognised, albeit variable, margin of appreciation, 
human-rights-based policy should not be ideology- 
or prejudice-driven, nor should it be judgmental. 
There is a strong case for redesigning drug policies if 
it is true that they are not achieving their objectives 
and, instead, have significant unwanted, undesirable 
or even unacceptable effects, all the more if they 
impinge on the enjoyment of human rights.
Kelly went on to discuss five articles in the European 
Convention on Human Rights (ECHR) and how drug policies 
can contravene each of them:
• Right to life (Art 2 ECHR)
• Prohibition of torture and inhuman or degrading 
treatment or punishment (Art 3 ECHR)
• Prohibition of forced labour/slavery (Art 4 ECHR)
• Right to liberty and personal freedom (Art 5 ECHR)
• Prohibition of discrimination (Art 14 ECHR)
Damon Barrett, Director of the International Centre on 
Human Rights and Drug Policy,4 took the argument further, 
arguing that drug prohibition per se is contrary to human 
rights, in other words, from a human rights perspective the 
use of criminal law to achieve a social goal is inappropriate.
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A glossary provides definitions of terms in common use to 
describe the preparation, use, effects and consequences,  
as well as common legal terms relating to the marketing of 
illicit drugs and official efforts to counter this.
1.  United Nations Office for Drug Control and Crime Prevention 
(2016) Terminology and information on drugs. Third edition.  
New York: United Nations. http://www.drugsandalcohol.
ie/5792/ 
terminology and 
information on drugs
The most recent revision of the UNODC’s Terminology and 
information on drugs1 presents introductory information 
on the better known psychoactive substances under 
international control. This includes both the scientific 
names of these substances and the names by which they 
are commonly known. The revision follows changes in the 
manufacturing and marketing of drugs and recent scheduling 
decisions by the Commission on Narcotic Drugs. 
The publication is a basic guide to patterns of abuse 
of these drugs, their effects and potential medical use. 
It also provides a useful explanation of the schedules 
in the international drug control treaties These were 
established to allow control of certain substances while 
ensuring their continued availability for legitimate medical 
and scientific purposes. 
The types of substances on which information is provided 
are cannabis; synthetic cannabinoid receptor agonists; 
opium and opiates; opioids; coca and cocaine; 
amphetamine-type stimulants; central nervous 
system depressants; and hallucinogens. 
PREVALENCE AND  
CURRENT SITUATION
health in Ireland: 
key trends 2015
Published by the Department of Health, this booklet provides 
summary statistics on health and health care in Ireland over 
the past 10 years.1 The data are organised in six chapters 
ranging from population, life expectancy and health status 
to health care delivery, staffing and costs. In the 
Introduction, the authors comment:
In the area of health determinants, lifestyle factors 
such as smoking, drinking, levels of physical activity 
and obesity continue to be issues which have the 
potential to jeopardise many of the health gains 
achieved in recent years. Furthermore, inequalities 
in health are closely linked with wider social 
determinants including living and working conditions, 
issues of service access, and cultural and physical 
environments. Taken together with an ageing 
population, adverse trends, if not addressed now, 
will lead to an unhealthy and costly future.
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Figure 1: Alcohol and cigarette consumption per annum among population aged 15 years and over, 
1994–2014
Source: Health in Ireland (2015) Figure 2.10, based on data from Revenue Commissioners and CSO
Note: Alcohol is measured in terms of pure alcohol consumed, based on sales of beer, cider, wine and spirits. 
Tobacco is measured in terms of sales of cigarettes recorded by the Revenue Commissioners. 
Figure 2: Daily smokers and persons classified as overweight or obese, by educational attainment, 2015
Source: Health in Ireland (2015) Figure 2.11, based on data in the Healthy Ireland Survey 2015
Alcohol and smoking
Figure 1 shows overall trends in alcohol and cigarette 
consumption over the last 20 years. Having levelled off over 
the last few years, the data for alcohol show an increase in 
consumption in 2014, following a drop in 2013. With respect 
to cigarettes, the declining figures based on excise duty data 
need to be treated with caution owing to the effects 
of cross-border and illegal sales.
Figure 2 shows the percentage of adults who are daily 
smokers or are overweight and obese by their educational 
attainment. In both cases, the rates of daily smoking and 
persons classified as overweight and obese are lower 
among those who attained a tertiary-level qualification. 
health in Ireland continued
15
Issue 57 | Spring 20
16
      drugnet IR
ELAN
D
      
treatment for problem drug use
Between 2005 and 2014 the number of cases treated for 
problem drug use in Ireland increased almost 52 per cent 
(Table 1). The number of new entrants into treatment also 
increased, but by a larger proportion (70%). The authors of 
the most recent bulletin on NDTRS and CTL data on treated 
problem drug use,3 which revealed a similar 52 per cent 
increase between 2005 and 2010, commented that the 
‘clear spread and increase in treated drug use throughout 
the country’ reflected ‘not only the extent of problem 
drug use but also an increase in treatment availability and 
compliance with the NDTRS’, an observation which is still 
pertinent today.
The number of people who drink more than six standard units 
of alcohol at least once a month, broken down by gender and 
social class, can be seen in Figure 3. It shows that men and 
those in the lower social group are more likely to engage in 
risky single-occasion drinking at least once per month. 
The results of the Irish Health Behaviour in School-aged 
Children (HBSC) survey 2014, when compared to the HBSC 
survey of four years earlier, show that the proportion of Irish 
children aged 10–17 years who are current smokers or who 
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Figure 3: Risky single-occasion drinking (6 or more standard 
units) at least once per month in the previous 12 months, by 
gender and socio-economic classification, 2015
Source: Health in Ireland (2015) Figure 2.12, based on data in the Healthy 
Ireland Survey 2015
Notes: (1) Risky single-occasion drinking is defined as six or more standard 
drinks. (2) Sample refers to those who regularly drink alcohol (n=5,694) 
according to the Healthy Ireland survey and excludes those who never 
drink alcohol/abstain (n=1,845)
Figure 4: Child health behaviours in smoking, alcohol and 
physical activity in Ireland, 2010 and 2014
Source: Health in Ireland (2015) Figure 2.13, based on Health Behaviour in 
School-Aged Children (2014)
Table 1: Number of cases in treatment for problem drug use and rate per 100,000 aged 15–64 years, 2005–2014
% Change
 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2005-2014 2013-2014
All cases in treatment* 12,101 12,737 13,597 14,518 14,933 16,429 16,329 16,286 17,375 18,342 51.6 5.6
New entries into 
treatment each year†
2,054 2,278 2,476 2,716 2,970 3,270 2,978 3,008 3,205 3,491 70.0 8.9
per 100,000 
15-64 year olds
72.8 78.3 82.0 88.0 95.9 106.1 97.1 98.9 106.2 116.1 59.5 9.3
Sources: Healthy Ireland (2015) Figure 4.6
* Central Treatment List (n=9,296) and National Drug Treatment Reporting System (NDTRS) (n= 9,046)
†NDTRS only
Notes: (1) Each record in the NDTRS database relates to a treatment episode (a case) and not to a person. This means that the same person could be counted 
more than once in the same calendar year if he/she had more than one treatment episode in that year. Additionally, the same case may appear in both the CTL 
data and the NDTRS data as there is no unique identifier yet in Ireland. (2) Both the CTL and the NDTRS data exclude those treated in prison. (3) NDTRS data for 
2014 is preliminary. (4) NDTRS does not include cases treated for alcohol as a main problem drug. 
have ever been really drunk have both declined over the 
four year period (Figure 4). A review of the trend in the level 
of lifetime drunkenness among Irish school-aged children 
between 1998 and 2014 shows that it decreased over the 
20-year period and most markedly among 13–15-year-olds.2 
This overall trend is welcome, especially among younger 
teenagers, as the immaturity of their brains makes them 
particularly vulnerable to the harmful effects of alcohol. 
Delaying initiation of drinking also decreases the likelihood 
of developing alcohol dependence in later life. 
Brigid Pike
1. Department of Health (2015) Health in Ireland: key trends 2015. 
Dublin: Department of Health. http://www.drugsandalcohol.
ie/24955/ 
2. Mongan D (2016) Health behaviour in school-aged children 
Drugnet Ireland (56) 14–16. http://www.drugsandalcohol.
ie/25144/ 
3. Bellerose D, Carew AM and Lyons S (2011) Trends in treated 
problem drug use in Ireland 2005–2010. HRB Trends Series 12. 
Dublin: Health Research Board. http://www.drugsandalcohol.
ie/16381/ 
health in Ireland continued
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16 • 14 (67%) were currently on methadone maintenance 
treatment.
• 3 (14%) were on Suboxone treatment.
• Several had a history of use of other illicit drugs.
themes emerging from interviews
Two higher-level concepts emerged from the analysis of the 
interviews – (1) emotional pain and user self-legitimisation 
of use, and (2) entrapment into habit-forming and invisible 
dependent use. In addition, the authors identified 10 themes 
with 82 categories. Some of the themes are highlighted below.
Awareness of habit-forming use and harm
Most interviewees reported that they were not aware 
that codeine was addictive or of the potential harms of 
ibuprofen and paracetamol. While only two said they had 
read the product information leaflet, most felt prescribing 
doctors should provide more information about use and the 
associated risks. Almost all had accessed the internet to 
learn which products contained codeine.
Negotiating pharmacy sales
All reported accessing codeine mainly from pharmacies. 
This often involved going to many different pharmacies in 
different locations and at different times in order to avoid 
suspicion. All were aware of the restrictions on the sale 
of codeine products and adapted to circumvent these 
measures. If an interviewee had been recognised by staff, 
they reported evasion tactics such as purchasing other 
products. However, interventions from pharmacists did 
sometimes lead participants to think about misuse. 
Alternative sourcing routes
Interviewees reported asking family members or friends to 
purchase codeine products or obtain prescriptions on their 
behalf, crossing the border or travelling to areas with less 
strict rules around codeine products, ‘doctor shopping’ 
with stories of pain, and forging prescriptions. Two 
interviewees who were healthcare professionals reported 
stealing from work.
the codeine feeling
Most interviewees started to use codeine for legitimate 
pain-related reasons. However, many described how they 
progressed within several weeks to taking the drug for its 
pleasurable effects or for emotional reasons rather than to 
alleviate physical pain. 
I had really no treatment [for depression] but I was 
totally dependent on the codeine, codeine was my 
treatment, codeine was my life.
the daily routine and acute and chronic side-effects
Interviewees reported that misuse started within weeks, 
often involving intense cravings and the need to take codeine 
‘to feel normal’ and to get though the day. Maximum daily 
consumption ranged from 24 to 115 tablets. Although many 
did not exceed the recommended dose, they misused the 
products over a long period. Several commented on the 
cost and time spent supporting their misuse. Reported 
side-effects included distorted vision, itching, constipation, 
rebound headaches, nausea, loss of appetite and of weight.
misuse and 
dependence on 
codeine-containing 
medicines 
Concerns have been growing globally regarding the misuse 
of both prescribed and over-the-counter (OTC) codeine, 
with research showing that both demand for codeine and 
misuse of OTC codeine have increased. In 2010 the Irish 
Pharmacy Regulator published guidance for pharmacists on 
the safe supply of non-prescription codeine-in-combination 
products to patients.1 This guidance was published following 
the enactment of the Pharmacy Act 2007 2 and the 
Regulation of Retail Pharmacy Businesses Regulations 2008.3 
The guidance states that these products are to be supplied 
only as ‘second-line’ medicine for pain-relief treatment. 
Detailed advice is also to be provided to patients about the 
correct short-term use of the products.
‘Codeine is my companion’
Following the above changes, a study was undertaken in 
Ireland to obtain individual and collective experiences of 
codeine use, and to gain an understanding of the pathways 
to misuse and dependence and of people’s experiences 
of treatment services.4 It was a qualitative study, based 
on in-depth interviews with 21 adult codeine ‘misusers’ 
(either currently using, in treatment or recovery) who were 
accessing, or had accessed, treatment services, and with 
their dependants. 
To date, there have been only a few Irish studies on problem 
codeine users. These have shown that users tend to be male, 
with a history of psychiatric problems, co-existing medical 
problems and/or poly-drug use. Quantifying the extent of 
misuse or dependence on codeine-containing medicines in 
Ireland has been difficult. The authors of the research study 
cite data from the National Drug Treatment Reporting System 
(NDTRS) for the period 2008–2012, which show that 1.9 per 
cent of people in drug treatment in Ireland had reported 
codeine as their primary or secondary problem drug.
Severity of dependence
Interviewees all completed the severity of dependence 
screener (SDS).5 Just over half of interviewees were women 
(12, 57%); their ages ranged between 26 and 62 years, with 
71 per cent being aged between 30 and 49; and 52 per 
cent were unemployed. With regard to substance use, the 
interviewees reported as follows:
• 15 (71%) had used codeine within the last 12 months. Of 
these, 12 (80%) scored 10 points or higher in the SDS. 
• 18 (86%) used codeine as their primary problem drug. 0f 
these, two (11%) reported using other opiate-type drugs, 
and 13 (62%) reported using codeine in combination 
with ibuprofen (e.g. Nurofen plus) as their primary drug 
of use. This combination was described by many of 
the interviewees as ‘optimal for intoxication purposes’ 
as opposed to other combinations, particularly with 
caffeine, which caused unwanted side effects such 
as nausea. 
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Conclusions
This qualitative study gives an additional perspective on 
codeine misuse and dependence addiction in Ireland, 
highlighting the roles of habit-forming use (encouraged 
by covert behaviours) and of self-medication for the 
relief of emotional distress in addiction formation. Given 
the availability of codeine-containing products and the 
lack of uniformity in diagnosing what is misuse of opioid 
pharmaceuticals, interventions for referral, treatment and 
management of codeine misuse remain limited.
The authors highlight the need to improve treatment 
pathways, and the availability and management of treatment 
for this group. They also highlight the need to proactively 
tackle the availability of codeine-containing medicines, 
minimise the risks associated with use when required 
for pain relief, and enhance consumer awareness. These 
initiatives need to be driven by both public health and 
regulatory bodies. 
Derek o’Neill
1. Pharmaceutical Society of Ireland (2010) Non-prescription 
medicinal products containing codeine: guidance for 
pharmacists on safe supply to patients. Retrieved 1 April 2016 at 
http://www.thepsi.ie/Libraries/Consultations/Final_Codeine_
Guidelines.sflb.ashx 
2. Pharmacy Act 2007 (Private Act No. 20 of 2007). Retrieved 1 
April 2016 at http://www.irishstatutebook.ie/eli/2007/act/20/
enacted/en/html 
3. Regulation of Retail Pharmacy Businesses Regulations, 2008 
(S.I. No. 488 of 2008) Retrieved 1 April 2016 at http://www.
irishstatutebook.ie/eli/2008/si/488/made/en/print 
4. Van Hout MC, Horan A, Santlal K, Rich E and Bergin M (2015) 
‘Codeine is my companion’: Misuse and dependence on codeine 
containing medicines in Ireland Irish Journal of Psychological 
Medicine, Early online, pp. 1–14. http://www.drugsandalcohol.
ie/24912/ 
5. Severity of Dependence Screener is a five-item questionnaire 
used to determine dependence in the past 12 months in order 
to determine dependent and non-dependent use. 
Social isolation
Social isolation and the damaging effect of addiction on 
family relationships were noted by some interviewees. The 
preoccupying nature of the dependence on codeine was 
cited as a reason for isolation from family and friends.
I don’t really have any friends any more. My friends 
are gone and it’s more a companion addiction. It feels 
like it has its arm around you. That’s how it is for me 
now. It gives me that sense of security and that’s 
what I am struggling with at the moment, it’s to break 
that cycle.
Withdrawal and dependence 
The side-effects of withdrawal were one of the reasons 
several interviewees reported for continuing misuse, trying 
to self-regulate the amounts taken to keep up normality. 
Many had unsuccessfully tried to self-detox.
I tried to cut down on it, gradually cut down, and 
then I’d just have a bad day and I’d be straight back 
up to 24 [tablets].
help-seeking and treatment experiences
There was an overall positive feeling towards treatment 
services and pharmacists when seeking help. The barriers 
to treatment revolved largely around the stigma associated 
with addiction and being labelled a drug addict. All the 
interviewees who commenced on tapered doses of codeine 
phosphate relapsed, reporting it did nothing to alleviate their 
cravings. Suboxone, however, was viewed very positively 
by the two individuals who took the drug, removing both 
cravings and withdrawal symptoms.
It was a miracle, a door opened for me, I was able 
to function, I was on no codeine. I actually walked 
into the chemist and I apologised to everyone who 
I had fooled.
Some interviewees indicated a preference for more 
involvement by pharmacists, rather than mainstream drug 
treatment facilities, in assisting treatment of addiction.
the internet and 
drug markets
Probably the most profound change in the market for illicit 
drugs over the past twenty years has been the proliferation 
of synthetic psychoactive substances, sometimes designed 
to mimic the effect of traditional plant-based drugs. 
Alongside this emergence of a vast range of new drugs, the 
mechanisms by which users obtain drugs are also being 
rapidly transformed. While the deal on the street corner 
or supply by a friend still dominate exchange in illicit drug 
markets, online purchasing is becoming a more common 
form of transaction. 
A recent collection of studies published by the EMCDDA 
points out that almost any kind of drug can be purchased 
on line and delivered through the postal system without 
any direct contact between buyer and provider. 1 Given the 
nature of the illicit drug market, offline encounters bring 
with them considerable risk of physical harm or arrest. The 
anonymity provided by the internet offers a degree of safety 
to both buyer and seller who can operate from whatever 
location they choose. It also offers the potential for markets 
to expand rapidly, still operating in a covert manner. 
As our economic and social lives move increasingly online, 
the threats to privacy and personal security from those who 
wish to use our information is a constant theme in public 
discourse around internet usage. Countering such threats is 
a significant driver of new internet technology and innovation 
in this area is expertly exploited to keep criminal activity 
hidden. This collection of papers examines several aspects 
Codeine-containing 
medicine continued
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16 significant arrest continues. As in the conventional market, 
vendor reputation is important and John Cox explains how 
vendors need to score well on a sophisticated rating system 
if they are to establish themselves in this market.
Eileen Ormsby studied the Silk Road for many years and 
presents her insights into the motives, political outlook 
and concerns of those who administered it or engaged 
in this cryptomarket as buyers or sellers. As happens in 
conventional markets this type of virtual market presents 
opportunities for harm reduction interventions. The 
experience of a medical doctor providing advice to users of 
online drug markets are recounted in a separate chapter. 
Enforcement and monitoring 
Two chapters examine the criminal aspects of dark net 
markets, the nature of supply and trafficking online and the 
efforts of law enforcement to counter illegal activity in this 
sphere. A chapter on the I-TREND (Internet Tools for Research 
in Europe on New Drugs) project describes a method for 
monitoring online NPS shops using specially designed software 
which builds on the snapshot studies conducted in this area 
since 2012. The project identified 584 online shops, 18 per cent 
of which were duplicates designed to distract attention from 
the original site. It is a very dynamic market which is difficult to 
monitor, but improvements in method indicate a considerable 
expansion in reliable data on use, retailers’ marketing 
approaches and the survival rates of such online enterprises.
Emerging issues
Technological innovations in encryption, digital currencies 
and browsing are key drivers of change in online drug markets. 
These facilitate anonymity for the seller, from both organised 
and ‘disorganised’ crime sectors, and for the buyer, as well 
as greatly reducing the risk of harm from violence as those 
involved in transactions do not have to meet. 
Social activism and the personal benefits of membership 
of an online community attract a wide audience to the 
user forums and discussion boards which gather around 
cryptomarkets and expand the potential pool for buyers of 
products online. The popularity of this social media, and the 
willingness of those who contribute to them to offer advice, 
opinion and provide important market feedback, present a 
rich opportunity to research this environment and provide a 
greater understanding of the operation of the dark web. 
This type of research will be relevant not just for uncovering 
the mechanisms of the market itself but for providing 
insights into how the existence of these markets affects 
drug use and the consequences of this use. These concerns 
and the manner in which the internet may provide both 
expansion of supply and opportunities for harm reduction 
interventions will probably be the focus of research in this 
area in the coming years.
Brian Galvin
1. European Monitoring Centre for Drugs and Drug Addiction (2016) 
The internet and drug markets Luxembourg: Publications Office 
of the European Union. http://www.drugsandalcohol.ie/25187/ 
2. European Monitoring Centre for Drugs and Drug Addiction (2014) 
The internet and drug markets: Summary of results from an 
EMCDDA Trendspotter study. Lisbon: EMCDDA. http://www.
drugsandalcohol.ie/23352/
3. Buxton J and Bingham T (2015) The rise and challenge of 
dark net drug markets Global Drug Policy Observatory. Wales: 
Swansea University. http://www.drugsandalcohol.ie/23274/
 
of the role of the internet in drug markets and is a very 
useful overview of this topic and builds on a growing body 
of work in this area in recent years.2,3
the surface web
The extent to which online communication is, or can be, 
hidden defines the various levels at which business is 
conducted on the internet. Online pharmacies and other 
sources of non-controlled substances use the accessible 
surface web. This is also the level at which new psychoactive 
substances (NPS) can be exchanged between countries with 
differing levels of control and where discussion around new 
drugs takes place on social media. NPS are often sold on 
the surface web as ‘research chemicals’. While sales of NPS 
in dark net markets are increasing, the surface web, where 
most online shops and pharmacies are based, is the most 
common source of new drugs. 
the dark net
Below the surface web, in parts of the internet not accessible 
to standard web browsers, is where the dark net markets or 
cryptomarkets operate. This part of the web is only accessible 
using special software such as The Onion Router (TOR), which 
facilitates online anonymity and makes the type of clandestine 
exchanges used in the supply of illicit drugs possible, and 
bitcoin, a special trading currency for online transactions. 
Projects monitoring the dark net report that around 70 
per cent of all drug-related sales on cryptomarkets are for 
cannabis, ecstasy and cocaine-related products. 
Separate chapters in the EMCDDA collection of studies 
explain the technology behind the specialised browsing 
software and encryption and cryptocurrencies and how they 
have been used to hide the identity of both vendors and 
buyers in black market goods. 
the Silk Road
The Silk Road, established in 2011, is probably the best known 
drug-related cryptomarket. Apart from the guarantee of 
anonymity this website functioned in many respects like 
mainstream digital markets like eBay. The Silk Road was closed 
down in 2013 and its second iteration, along with 400 other 
deep web sites, were taken down in 2014. It is not clear 
yet how this disruption has affected the organisation of 
this market but it would appear that, following a period 
of increasing openness, the dark web is becoming increasingly 
closed and is often used as a means to facilitate one-to-one 
interactions between a seller and buyer looking for a secure 
supply. 
Judith Aldridge and David Décary-Hétu investigated the Silk 
Road before it was taken down and describe how they see 
the sale of drugs on the dark web impacting on the global 
drugs trade. They argue that, while currently online exchange 
comprises a tiny fraction of the overall drugs trade, it has 
the capacity to complement conventional trade by allowing 
the purchase of a wide range of substances that would 
not be available otherwise. The need to become adept 
at TOR-like technology, security fears and the degree of 
planning required may be limiting factors on the growth of 
this market. The removal of the threat of both violence and 
arrest may encourage greater use and growth is more likely 
if the recent pattern of disruption of cryptomarkets without 
The internet and 
drug markets continued
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Following an initial study using a Garda-designed research 
tool, the author of the 2009 report undertook a postal 
survey of a sample of 91 family support workers or 
facilitators, 50 of whom responded. The survey gathered 
information on the extent and nature of drug-related 
intimidation encountered by the respondents in the course 
of their work over the previous 12 months. The responses 
included case studies submitted by 36 respondents. Nearly 
all the respondents reported that they had clients, usually 
mothers of indebted drug users, but also including other 
family members, who had experienced intimidation because 
of drug-related debts, sometimes as low as €100 but more 
often amounting to several thousand euro. Little account 
had been taken of the capacity of these people to repay 
the debts, with most families needing to take out loans or 
sell property to do so. Nevertheless, payment was pursued 
relentlessly and participation in illegal activity, such as 
storing drugs or weapons or even prostitution, was often 
accepted as partial payment. This enforced criminality 
sometimes resulted in the exclusion of the family from their 
local authority home. Mothers were the family member most 
frequently targeted by those seeking repayment of a debt 
and it was usually an associate of the person to whom the 
debt was owed who made contact. Payment of the debt 
generally ended the intimidation, but most of the case 
studies reported that the drug user often incurred further 
debts and then the intimidation began again. The survey also 
collected information on the consequences of unpaid debts, 
with threats almost invariably being carried out. 
While verbal threats, including threats of sexual violence, 
were the most frequently recorded form of intimidation, 
physical violence and damage to property were almost 
as common. Intimidation has a profound effect on the 
communities where it is prevalent. Families who had 
experienced intimidation were too fearful to approach 
the Garda and it seems drug-related intimidation is a very 
under-reported crime. The 2009–16 National Drugs Strategy, 
following a recommendation from this 2009 report, included 
an action (Action 5) to develop a response to the problem 
of intimidation. FSN, together with the Garda and the Health 
Service Executive (HSE), developed a framework including 
training, an information leaflet and an online campaign 
to assist drug users, their families or friends who are 
experiencing drug-related intimidation.
melting the iceberg of fear 
A 2013 study of drug-related intimidation concentrated on 
one area of a Dublin suburb, interviewing people working in 
various health and community services.5 From the responses 
to the interviews, the author devised a ranking system for 
those engaged in drug-related intimidation, starting with a 
‘higher order’, comprising those in powerful positions in the 
illicit drugs market locally who organised intimidation of in-
debt users and other members of the community; a ‘middle 
order’, often drug users themselves, who were prepared 
to threaten to protect their own position or act on the 
instruction of others; and a ‘lower order’, mainly children, 
who were being initiated into drug dealing and engaging in 
antisocial behaviour at the behest of adults.
 
the drugs market 
and intimidation
We know from several international studies that the basic 
assumptions of the standard economic model do not apply 
to the market for illicit drugs.1 The existence of this market 
has consequences, often violent, for the distributors and 
buyers engaged in it as well as for the broader community. 
Earlier this year the nature of the intense rivalry among 
those involved in the importation and distribution of illicit 
drugs was underlined by a number of very public violent 
incidents in Dublin. The seemingly inevitable lethal outcome 
of disputes among competitors in this market receives a 
great deal of media attention, including profiles of prominent 
victims and background stories on how this usually 
clandestine business operates. 
A hidden but more frequently occurring harm is the violence 
and threat of violence experienced by drug users and their 
families within their own communities as a result of debt 
incurred through drug use. The willingness of distributors 
to use or threaten violence to enforce debts or overcome 
obstacles has a profound impact on communities already 
dealing with the disorder and property crime resulting 
from the concentration of drug markets in their areas.2 
Intimidation, by its nature, uses fear to both force people 
into certain actions and ensure silence. It is therefore a 
very difficult topic to study and while anecdotally we know 
intimidation is used intensively in certain communities, the 
extent of its use and the consequences for the victims have 
not been systematically measured. 
A recent CityWide study, Demanding money with 
menace,3 recorded and categorised incidents reported to 
community-based drug services which have not, generally, 
come to the attention of the Garda. This research built on 
the knowledge obtained through two previous studies, which 
had used innovative approaches to illuminate the nature and 
consequences of this phenomenon. 
Intimidation of families 
A 2009 report on drug-related intimidation, published by 
the Family Support Network (FSN),4 put the findings in the 
broader context of families already living in marginalised 
communities and undergoing further alienation as a result 
of official indifference and even hostility. Having a family 
member being threatened with, or actually experiencing, 
violence as a result of drug use was found sometimes 
to elicit little sympathy from statutory agencies, leaving 
affected families to cope on their own. While communities 
often organised themselves in a collective response to the 
open sale of drugs in certain areas, the author of the report 
described how drug users themselves were sometimes 
targeted by this communal activism, compounding their 
already difficult situation. From their work with families 
of deceased drug users FSN was well placed to articulate 
concerns around the specific problem of drug-related 
intimidation and explore means of alleviating its worst 
effects on the communities in which criminal organisations 
were active. 
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16 The responses of victims and their families to drug-related 
intimidation vary, with slightly less than half of debts being 
paid in full. Some individuals and their families took no 
action while just over one in five avoided the perpetrators. 
A little over a third of those reporting incidents had informed 
the Gardaí, with community organisations being the 
organisations to which intimidation was most often reported. 
Fear of reprisal was the reason most people gave for not 
reporting to the Gardaí and, even if prosecution did follow, 
this was no guarantee that the intimidation would cease. The 
consequences for victims of intimidation and their families 
can be severe, with more than two thirds reporting mental 
health problems arising from both the intimidation itself and 
the attendant relationship problems, financial worries and 
stress in the workplace.
The CityWide report emphasises the role played by 
community services in supporting those targeted by 
intimidation and calls for these services to be adequately 
equipped to deal with these distressing situations. Young 
people’s indebtedness can rapidly lead to criminal activity, 
so early preventative work and intervention to stop gang 
formation is also important. According to the authors, the 
normalisation of drug-related intimidation and the degree 
to which it is under-reported owing to fear and lack of 
confidence in the policing system are major criminal justice 
issues which require resources and the attention of all 
relevant agencies to resolve.
Brian Galvin
1. LSE Expert Group on the Economics of Drug Policy (2016) 
After the drug wars. Report of the LSE Expert Group on the 
Economics of Drug Policy London School of Economics. http://
www.drugsandalcohol.ie/25200/ 
2. Connolly J and Donovan AM (2014) Illicit drug markets in Ireland 
National Advisory Committee on Drugs and Alcohol, Dublin 
http://www.drugsandalcohol.ie/22837/ 
3. Connolly J and Buckley L (2016) Demanding money with 
menace: drug-related intimidation and community violence 
in Ireland Dublin: Citywide Drugs Crisis Campaign. http://www.
drugsandalcohol.ie/25201/ 
4. O’Leary M (2009) Intimidation of families Dublin: Family Support 
Network www.drugsandalcohol.ie/12898
5. Jennings P (2013) Melting the iceberg of fear: a collective 
response Dublin: Safer Blanchardstown. http://www.
drugsandalcohol.ie/20566/ 
6. Hourigan N (2011) Understanding Limerick: social exclusion 
and change. Cork: Cork University Press
Demanding money with menace 
The 2016 CityWide study, mentioned above, undertook an 
audit of drugs projects in local and regional drug and alcohol 
task force areas to gather information on intimidation that 
had been reported to these projects. Most task forces 
agreed to participate in the audit and collaborated with 
the authors in the design of the questionnaire on which the 
audit was based. The authors used a series of focus groups 
with both local and regional drugs and alcohol task forces 
to explain the purpose of the audit, garner local information 
on the subject and distribute the questionnaires. Project 
workers in the participating task force areas completed the 
questionnaires and returned them to CityWide between April 
2014 and December 2015. To complete the audit the authors 
held further focus groups, which were used to complement 
and clarify the findings from the returned questionnaires. 
They also undertook focus groups with Travellers, former 
prisoners and various community groups. 
The findings of the CityWide audit were similar to those of 
the 2009 FSN study in a number of respects. After the drug 
user who had incurred a debt, the person most likely to 
be a victim of intimidation was the debtor’s mother. These 
were also the people most likely to report threats of, or 
actual, violence. The drug user was often the source of 
intimidation, putting pressure on his or her own family to 
pay money owed as result of drug use. While verbal threats 
formed part of three quarters of all intimidation incidents 
reported, physical violence (46%) and damage to property 
(32%) were very common. As was found in the FSN study, 
coercion into criminal activity often resulted from failure to 
pay a drug debt. As supply of drugs on credit is a feature of 
the illicit drug market, violence is seen not just as a means 
of enforcing a debt but also as a means of warning other 
drug users about the consequences of not paying debts. 
The increasingly heavy use of cannabis among young people 
has meant that the age profile of those incurring debts has 
declined. Just over 40 per cent of debts are for sums of less 
€1,000 but the pressure to pay relatively small debts is just 
as intense as for greater sums. A little over a quarter of debts 
were for sums of €1,000 to €5,000, with nearly 13 per cent 
ranging between €5,000 and €10,000.
The role played by gangs in the acquisition and distribution 
of drugs in marginalised communities has been 
documented,6 and intimidation, or enforcement of debt, 
is also frequently organised and carried out by groups of 
people. Most of the incidents recorded in the CityWide 
audit involved groups of people: existing social networks 
attempt to establish themselves in the drugs trade and such 
groupings are necessary to maintain clandestine activity. 
Young people are generally acquainted with those who 
intimidate them, often belonging to the same social 
network and enduring the consequences of falling into 
debt with friends. 
drugs-related intimidation 
continued
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For many families, this service is the first time that they 
can openly grieve for their loved ones lost to drug use and 
related causes. The growth of family support groups was 
evident, with representatives from over 100 groups from 
across the island of Ireland represented at this year’s service. 
Personal testimonies were given by members of family 
support groups, reflecting the vital support received through 
these groups. These included Pauline Doyle, a member of 
the NFSN Bereavement Support Group, who acknowledged 
the tremendous work of the NFSN Bereavement Support 
Group and encouraged family members to contact the NFSN 
and avail of the help it offers. The support she received help 
alleviate the shame she felt and allowed her healing process 
to begin. Paul Grace gave a very honest and emotional 
speech about his experience as a drug user. He admitted 
feeling too ashamed to ask for help, ashamed of failure. He 
called for more encouragement from treatment providers 
to help people ‘get clean’ and the expansion of treatment 
beyond medication. 
Guest speaker Elizabeth Burton-Phillips spoke about her 
journey of bereavement following the death of her son 
Nick and the publication of her book Mum, can you lead 
me twenty quid?, which is also being turned into a play. 
She encouraged the audience never to give up hope. 
You can contact the National Family Support Network at
16 Talbot Street, Dublin 1. 
Tel: 01 898 0148 
email: info@fsn.ie
web: www.fsn.ie 
Ena lynn
1. Health Research Board (2015) Drug-related deaths and deaths 
among drug users in Ireland: 2013 figures from the National 
Drug-Related Deaths Index. Dublin: Health Research Board. 
http:// www.drugsandalcohol.ie/24676 
RESPONSES
17th annual Service 
of Commemoration 
and hope
On Monday 1 February 2016 the National Family 
Support Network (NFSN) held its 17th annual Service 
of Commemoration and Hope. This spiritual, multi-
denominational service is held in remembrance of loved 
ones lost to substance misuse and related causes, and to 
publicly support and offer hope to families living with the 
devastation that substance misuse causes.
Those in attendance included President Michael D Higgins; 
Charlie Dineen, aide-de-camp to the Taoiseach; Aodhán 
Ó Ríordáin TD, Minister of State with responsibility for 
Drugs; Joe Costello TD; Garda Commissioner Noirín 
O’Sullivan; Deputy Lord Mayor Cieran Perry; Bishop Eamonn 
Walsh and other religious representatives. Family members, 
friends, and many people working in the drugs area also 
attended. Music was provided by the soprano Nickola 
Hendy and the Dublin Gospel Choir.
In her address to the gathering, Sadie Grace of the  
NFSN spoke about the latest report from the National 
Drug-Related Deaths Index,1 which shows an increase 
in drug-related deaths. She spoke about the increase 
in deaths owing to heroin use and how the majority of 
deaths involved young men. She also mentioned the role 
of naloxone in helping prevent deaths from opiate overdose 
and the NFSN’s support for the HSE naloxone demonstration 
project. She stressed the importance of expanding the 
availability of naloxone to family members and educating 
families on the signs and symptoms of overdose.
Sadie spoke about the impact of compounding factors 
affecting bereaved families associated with drug-related 
deaths, such as increased financial difficulties related to 
funerals, and single parents or kinship carers taking on the 
responsibility of caring for young children. She called for 
more research in this area. In her closing statement she 
called on the audience to canvass their local TDs to ensure 
their political parties support the appointment of a specific 
minister with responsibility for the drugs strategy. 
Minister Aodhán Ó Ríordáin TD congratulated the NFSN 
on its excellent work and spoke about the current crisis 
in relation to drug-related deaths. He acknowledged the 
feeling of shame felt by drug users seeking treatment and by 
family members in seeking help. He spoke about this feeling 
of shame leading to wrongful acceptance of second-rate 
treatment. In his address, Bishop Eamonn Walsh spoke of 
the importance of moving from reliance on artificial highs to 
embracing natural highs through nature, sport, music, dance 
and the arts.
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16 A community 
partnership for 
tackling hepatitis C
University College Dublin (UCD) and the Dublin Academic 
Health Centre (the Mater Hospital and St Vincent’s 
Hospital) have successfully competed for a European Union 
(EU) health care award funded by the Third EU Health 
Programme, which focuses on implementing the EU health 
strategy. The successful HepCare Europe project will 
develop community partnerships for tackling the hepatitis C 
virus (HCV), which causes significant morbidity and mortality 
in Ireland and the EU. 
The HepCare Europe project, submitted by Dr Jack Lambert 
(Mater Hospital) and Professor Walter Cullen (UCD School of 
Medicine), was approved in December 2015. It was the only 
successful application among four made under this call from 
across Europe for proposals focusing on community HCV 
partnerships. It is a three-year project involving populations 
at risk of contracting HCV in four member states, specifically 
in the cities of Dublin, London, Seville, and Bucharest. HCV 
is a major health threat in the EU, with the complications 
of undiagnosed and untreated HCV leading to end-stage 
cirrhosis and hepatocellular carcinoma. The grant awarded to 
UCD, totalling approximately €1.8 million from the EU and ‘in 
kind’ contributions from Irish government health agencies, 
will target ‘vulnerable’ populations.
HCV is deemed a disease of the socially-deprived, affecting 
primarily those with a history of injecting drug use. Many 
of these patients are not accessing care for a number of 
reasons, including active drug use, alcoholism, mental health 
issues and homelessness. In the last two years a medical 
revolution has seen the development of HCV drugs, called 
direct-acting antivirals, which can cure almost all those 
who receive an evaluation and treatment. Treatment 
consists of one or two pills administered orally each day 
for a period of often just 12 weeks. The treatment has 
led to cures and reversals among those with advanced 
HCV-related liver disease. 
The HepCare Europe project will focus on providing 
‘integrated care’, a new model for HCV treatment based on 
a partnership between secondary caregivers (the Hepatology 
and Infectious Diseases Services at the Mater and St 
Vincent’s hospitals) and primary caregivers, i.e. GPs and 
drug treatment centres in Dublin. The project will reach 
out to drug users and:
• identify those not accessing care, by using rapid 
HCV testing;
• provide peer support (using community-based 
organisations) to assist those identified with HCV 
to access care; and
• develop nurse liaison links so that the secondary 
caregivers will go to the patient, rather than the 
patients going to the secondary caregivers. 
Patients will be tested in the community and have their HCV 
evaluated in the community by means of a novel fibroscan 
test, which has replaced liver biopsy, to assess the degree 
of hepatic impairment caused by HCV, and community-
based treatments will be piloted. Other supports to patients 
will include interventions to help reduce or cease alcohol 
consumption, which is a significant problem among these 
vulnerable individuals. 
In addition to outreach, the project will involve education 
of caregivers and patient groups about HCV and the new 
curative treatments available. The University of Bristol in the 
UK, an institution that has championed cost-effectiveness 
studies and evaluations of interventions in HIV and HCV, are 
partners in the Hepcare Europe project, and will provide 
cost-effectiveness evaluations of the interventions planned 
as part of this EU-funded project. 
John S lambert, mD, PhD
Consultant in Infectious Diseases, Medicine and Sexual 
Health (GUM), Mater, Rotunda and UCD
Telephone: + 353 1 716 4530 (office) 
Mobile: + 353 87 261 3778
take-home 
naloxone
This article describes some of the findings of a report 
Preventing opioid overdose deaths with take-home naloxone,1 
recently published by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA). Opioid users are 10 
times more likely to die of an overdose than their age- 
and gender-matched peers.2 
Data presented in the EMCDDA report indicate that between 
6,000 and 8,000 drug-related deaths occur every year in 
Europe and that opioids account for the majority of these 
deaths. In Ireland in 2013, there were 203 deaths in which 
opioids were implicated.3 Of these 203 individuals, 93 (46%) 
were not alone at the time of death, suggesting that an early 
intervention, such as the administration of naloxone, may act 
to prevent opioid-induced deaths in Ireland.4
opioids and naloxone
Opioids are highly addictive compounds that reduce pain 
by binding to their receptors in the brain and body, and by 
reducing the intensity of pain signals reaching the brain. A 
side-effect of opioid use is reduced breathing capacity, i.e. 
respiratory depression. 
Naloxone is a semi-synthetic drug, which prevents opioids 
from binding to opioid receptors in the brain and body, 
and reverses respiratory depression. Naloxone is capable 
of reversing respiratory depression within one to two 
minutes if administered intravenously; with intramuscular 
or subcutaneous delivery, the effect takes longer, typically 
three to four minutes. In order to make naloxone use 
more user-friendly for non-medically trained individuals, 
alternative routes of administration have been explored. 
Intranasal (in the nose) preparations and buccal (in the 
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establishing take-home naloxone programmes. Overall, data 
in the EMCDDA report suggest that opioid users and their 
families are receptive to participating in take-home naloxone 
programmes. 
legal issues
The legality of administering naloxone to someone other 
than the person it was prescribed for has been a dominating 
issue. Both professionals and servicer users have expressed 
concern about the risk of civil or criminal prosecution. The 
United States, Germany, the Netherlands, Luxembourg and 
the UK have passed versions of ‘Good Samaritan’ law, which 
absolves the person in the event of administering naloxone to 
save a life. In Italy, naloxone is available over the counter so is 
not subject to legislation regarding prescription.
take-home naloxone in Europe and in Ireland
In 2014 data were presented at an EMCDDA meeting in Lisbon 
regarding take-home naloxone use in Europe.5 Among the 
24 member states who responded, naloxone was available 
on medical prescription in 13 and limited to hospital-
only prescription in a further 11 countries. None of the 24 
responding countries currently had a national take-home 
naloxone programme. However, programmes existed in cities or 
regions across Europe, including Denmark, Germany, Ireland, 
Italy, Norway, Spain and the UK, and data from these studies 
are expected to prompt nation-wide programmes in some 
countries. Outside Europe, there are take-home naloxone 
programmes available in the USA, Australia, Canada and Russia. 
In Ireland in May 2015, the Health Service Executive (HSE) 
established a take-home naloxone project that will assess 
the efficacy of take-home naloxone in preventing drug-
induced deaths, with an initial target of 600 participating 
opioid users. Participants are required to learn by video-
training about overdose signs, risk factors, administration of 
naloxone, and basic life support. If knowledge of these can 
be shown, the participant is given a take-home naloxone kit. 
Looking to the future, it is strongly recommended that 
take-home naloxone programmes and the rate of associated 
overdose mortality be rigorously monitored in order to 
adequately evaluate its success, sustainability and cost 
effectiveness. No evaluation data relating to the HSE’s 
project are available yet.6 
Aoife Cannon
1.  EMCDDA (2016 ) Preventing opioid overdose deaths with 
take-home naloxone. Luxembourg: Publications Office of the 
European Union. http://www.emcdda.europa.eu/publications/
insights/take-home-naloxone 
2. EMCDDA (2015) European drug report 2015: Trends and 
developments. Luxembourg: Publications Office of the European 
Union. http://www.emcdda.europa.eu/edr2015
3. Health Research Board (2015) Drug-related deaths and deaths 
among drug users in Ireland: 2013 figures from the National 
Drug-Related Deaths Index Dublin: Health Research Board. 
http:// www.drugsandalcohol.ie/24676
4. Warner-Smith M, Darke S, Lynskey M and Hall W (2001) Heroin 
overdose: causes and consequences Addiction (96): 1113–1125.
5. Hughes, B. (2014), Distribution and use of naloxone: legal 
issues: Powerpoint presentation given in Lisbon, Portugal, 14 
October. Retrieved 26 April 2016 http://www.emcdda.europa.
eu/events/2014/meetings/naloxone
6. For more information on the HSE take-home naloxone project, 
visit http://www.drugs.ie/resources/naloxone 
 
mouth, against the cheek) are being assessed for their 
efficacy and may be more suitable for naloxone use in a 
non-clinical setting. 
Risk of overdose
People with an opioid dependency are the group most  
likely to experience an overdose. Risk factors for opioid 
overdose include:
• injecting opioids,
• loss of tolerance, 
• using opioids in combination with sedatives, 
• recent release from prison, 
• discharge from a residential rehab/detox, and
• using alone.
history of naloxone use
Since its discovery in the 1970s naloxone has been widely 
used in hospitals to reverse the effects of opioids. In the 
1990s, paramedics in the US were trained to use naloxone in 
suspected opioid overdoses outside of the clinic, in a bid to 
decrease opioid-associated deaths in the community. In one 
urban setting, a study revealed that 90-94 per cent of the 
487 individuals who received paramedic-delivered naloxone 
treatment responded rapidly, indicating that naloxone was 
a quick and effective treatment for opioid overdose in 
the community. 
Despite the fact that there have been over 40 years of 
data and experience on naloxone use in a medical setting, the 
concept of take-home naloxone is relatively new. An increase 
in opioid-induced deaths in Chicago in the early to mid-1990s 
spurred the Chicago Recovery Alliance (CRA) to commence an 
informal take-home naloxone programme in 1996. This is the 
first known established provision of take-home naloxone. The 
CRA trained service users in overdose prevention and provided 
them with take-home naloxone kits. Owing to the demand 
for the service, in 2001 CRA formalised the programme and 
standardised the training. Similar programmes were set up in 
Germany, Italy and the UK in the late 1990s. 
training for take-home naloxone
Data from a report published by the WHO in 2014 showed 
that many opioid overdoses occurred in the presence of 
other people. Based on this, three target groups for training 
in administering take-home naloxone were identified: (1) 
opioid users, (2) close family and friends and (3) services 
that interact with opioid users. Opioid users were the 
primary focus of many training programmes owing to the 
fact that they have a 50-70 per cent lifetime risk of having 
an overdose and also because they are likely to be a 
bystander at an overdose.3 
International research has found high levels of support among 
opioid users for take-home naloxone. However, opioid users 
have also expressed several concerns. These include questions 
about competency when administering naloxone in the event 
of an overdose, the legal repercussions regarding the carrying 
and use of naloxone, and anxieties about either those they 
have treated or they themselves experiencing withdrawal 
symptoms. The authors of the EMCDDAtake-home naloxone 
report recommend that concerns should be addressed when 
Take-home naloxone continued
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You can search our entire collection of Irish and international 
research using our simple or advanced search facilities. 
And our practitioner resource provides direct links to 
key documents and subjects relevant to health and  
social-care professions.
If you are looking for up-to-date Irish data, you may be 
particularly interested in our interactive drug-treatment 
and alcohol-diary data tables, found on the key Irish data 
page. Also on that page, you can access our factsheets on 
cannabis, cocaine, sedatives and opiates.
 
And our very first alcohol factsheet, compiled by the 
librarians, was recently published. Alcohol: the Irish situation 
draws together information on treatment, prevalence, 
mortality and crime in Ireland in one convenient document.
As librarians, we have a significant role to play in facilitating 
knowledge transfer and exchange. Throughout the research 
process we can provide relevant resources and services, 
culminating in the effective dissemination and use of 
findings. We will continue to engage with researchers and 
practitioners to achieve this ultimate goal.
mairea Nelson and mary Dunne
To coincide with the launch of the Health Research Board’s 
new strategy, the National Documentation Centre on Drug 
Use changed its name to the hRB National Drugs library 
in January 2016. We have refreshed our website 
www.drugsandalcohol.ie to reflect this change.
 We continue to provide the same range of resources and 
services to facilitate the use of research in decision-making 
by those working in the area of problem substance use.
There are a number of easy ways in which you can 
keep up-to-date:
• Follow us on twitter @HRBdrugslibrary, or sign up 
to receive links to new research straight to your 
email account.
• Read our quarterly research and policy bulletin, 
Drugnet Ireland, which provides summaries of recent 
Irish policy developments, events and research.
• Sign up to our monthly electronic newsletter with links 
to new publications, Dáil debates and news items.
Those working in the drugs area will be aware that 
drug-related research is highly complex, primarily rooted 
in physical and mental health, but also incorporating other 
areas such as criminal and social justice, social science, 
and education. 
SERVICES
hRB National Drugs library 
http://www.drugsandalcohol.ie/
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Coolmine launches new  
strategy 2016–2018
The Tánaiste, Joan Burton TD, launched Coolmine 
Therapeutic Community’s (CTC’s) new strategy for 2016 to 
2018 in the offices of Dublin City Council on 16 December 
2015.1 Acknowledging the impressive amount of work 
that had gone into the development of the strategy, she 
observed that at the heart of a successful plan is interagency 
co-operation in health, housing and social services. She 
specifically mentioned CTC’s Parents under Pressure 
Programme at Ashleigh House, the only family residential 
service in Ireland. 
Alan Connolly, chairman of Coolmine, and Pauline McKeown, 
CEO, also spoke, outlining the process of developing, and the 
objectives of, the new strategy.2 The new strategy contains 
12 objectives under two overarching strategic aims. 
Growth and innovation
• Develop a drug-free prison therapeutic community 
to increase the service provision for prisoners with 
problematic substance misuse issues in the Irish 
Prison Service.
• Scope out and develop the expansion of CTC’s mother 
and child services, including further programmes for 
non-stabilised pregnant women and the Parents under 
Pressure programme.
• Develop services to enhance treatment access, decrease 
early leavers and manage crises during lapse/relapse.
• Explore the potential for further non-residential 
community-based alcohol treatment services.
• Review and enhance partnership agreements to further 
increase access to treatment and rehabilitation services, 
support project expansion and maximise after-care 
supports nationally.
• Invest in CTC’s established research culture to 
identify opportunities that contribute both national 
and internationally.
Capacity and sustainability
• Identify and invest in staff and management structures.
• Conduct an annual review of governance arrangements, 
including clinical governance, charity regulation, and 
fund-raising principles.
• Develop comprehensive IT systems.
• Develop an annual maintenance plan for each service 
that reflects best practice in health and safety, is 
cost-effective and deliverable.
• Devise and deliver a communications strategy to enhance 
the national profile of the organisation and to secure 
CTC’s position as a treatment and rehabilitation centre 
of excellence.
• Develop and implement a three-year fund-raising 
strategy incorporating realistic income targets, 
sustainable growth and targeting opportunities locally, 
nationally and internationally.
Graduates of the Coolmine programme, Ann Marie Sweeney 
and Charles Lane, spoke eloquently about their journey with 
Coolmine and how engaging with treatment had helped to 
turn their lives round. Ann Marie is heading to college and 
Charles is now the client co-ordinator at Coolmine. 
Further information can be found at www.coolmine.ie 
Suzi lyons
1. Coolmine Therapeutic Community (2015) Coolmine strategic 
plan 2016–2018. Dublin: Coolmine Therapeutic Community. 
http://www.drugsandalcohol.ie/24927/
2. Videos of the speakers can be found at http://www.drugs.ie/
multimedia/video/launch_coolmine_strategic_plan_2016_20182
Pauline McKeown Coolmine 
CEO, Joan Burton TD 
and  Alan Connolly, 
Coolmine chair at the 
launch of Coolmine 
strategic plan 2016 - 2018
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Methadone treatment is one of a number of primary care 
reimbursement services (PCRS). These PCRS are delivered 
by over 7,000 primary care contractors such as general 
practitioners, pharmacists, dentists, optometrists and/
or ophthalmologists, who are reimbursed by the HSE. A 
key priority and action for 2016 relevant to methadone 
treatment is the implementation of the plan for the roll-out 
of individual health identifiers in 2016 in line with the Health 
Identifiers Act 2014 (p. 56).
Addiction and substance misuse
Addiction services are provided by Social Inclusion 
Services, the core objective of which is to improve health 
outcomes for the most vulnerable in society including Irish 
Travellers and Roma, asylum seekers, refugees and lesbian, 
gay, bisexual, transgender (LGBT) service users. Issues of 
addiction, substance misuse, homelessness and domestic, 
sexual and gender-based violence are overarching themes 
within the service user groups. Social Inclusion Services work 
with mainstream services and voluntary sector services to 
ensure accessibility for disadvantaged service users. 
The priorities and key actions to improve health outcomes 
for people with addiction issues include the following (p. 56): 
• implement the outstanding actions in the National Drugs 
Strategy (2009–2016);4
• ensure that adults deemed appropriate for treatment 
for substance abuse receive treatment within one 
calendar month;
• ensure that children deemed appropriate for treatment 
for substance abuse receive treatment within one week;
• ensure that addiction services operate within the 
person-centred care planning processes of the Drugs 
Rehabilitation Framework;5
• finalise the response to drug-related deaths through 
a National Overdose Prevention Strategy;
• audit drug services in line with the Drugs Rehabilitation 
Framework on care planning, assessment, key working 
and referrals; and
• strengthen clinical governance structures by the 
appointment of an Addiction Clinical Lead.
2016 access indicators (p. 63):
• Substance misusers (over 18 years) for whom treatment 
has commenced within one calendar month following 
assessment: 100% 
• Substance misusers (under 18 years) for whom 
treatment has commenced within one week following 
assessment: 100% 
• Number of clients in receipt of opioid substitution 
treatment (outside prisons): 9,515 
• Average waiting time from referral to assessment for 
opioid substitution treatment: 14 days
• Average waiting time from opioid substitution assessment 
to exit from waiting list or treatment commenced: 
28 days
• Number of unique individuals attending pharmacy 
needle exchange: 1,731
hSE national service 
plan 2016 
The HSE’s National Service Plan 2016 (NSP), approved by the 
government in December 2015, sets out the HSE’s priorities 
and targets for tackling tobacco use and alcohol and 
substance misuse in 2016.1 Initiatives are identified in three 
distinct areas – in the context of the Healthy Ireland policy 
framework, and within the HSE’s Primary Care Division and 
Mental Health Services.
healthy Ireland framework2
The key priorities and actions for tobacco and alcohol are 
listed under the goal of ‘promoting health and well-being 
as part of everything we do so that people will be healthier’ 
(pp. 45–49).
tobacco 
• Maintain and strengthen the HSE Tobacco Free Policy
• Maximise impact of the QUIT Campaign
• Make all new residential units tobacco-free
• Train frontline workers to support smokers to quit
2016 Quality Indicator: 45 per cent of smokers on 
cessation programmes quit at one month. 
2016 Access Indicator: 11,500 smokers received intensive 
cessation support from a cessation counsellor.
Alcohol
• Develop a three-year alcohol implementation plan 
to reduce alcohol consumption and related harms, 
incorporating actions from the National Substance 
Misuse report3 and aligned to new legislation.
• Develop and prepare the enforcement provisions of the 
Public Health (Alcohol) Bill 2015 in partnership with the 
Department of Health.
• Further progress a co-ordinated approach to prevention 
and education interventions through the community 
mobilisation on alcohol initiatives with drugs and 
alcohol task forces, and through the REACT award and 
accreditation scheme in the third-level sector, which 
recognises and rewards an institution’s efforts to reduce 
alcohol-related harm amongst its students.
• Increase awareness among the public of alcohol-related 
harm by building on the 2015 communication campaign.
Primary care 
Smoking and alcohol and illicit substance misuse are all 
addressed by the HSE’s Primary Care Division, which is 
responsible for primary teams (PCTs) and general practice, 
primary care reimbursement schemes (PCRS), social 
inclusion and palliative care services. 
Smoking 
As part of collaboration between Primary Care and Health 
and Wellbeing for Health, PCTs are to support brief 
intervention training for staff on smoking cessation (p. 54).
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Among the priorities for Mental Health in 2016 is the 
development of a new clinical programme specifically 
for dual diagnosis of mental illness and substance misuse 
including alcohol (p. 65).
Among measures to contribute to promoting the mental 
health of the population in collaboration with other services 
and agencies, including reducing loss of life by suicide, is 
an action to ‘develop an increased focus on the health and 
wellbeing of the population in the delivery of mental health 
services, including supporting the continued rollout of the 
Tobacco Free Campus policy’ (p. 65).
Brigid Pike
1. Health Service Executive (2015) National service plan 2016. 
Dublin: Health Service Executive. http://www.drugsandalcohol.
ie/24939/ 
2. Department of Health (2013) Healthy Ireland: a framework for 
improved health and wellbeing 2013–2025. Dublin: Department 
of Health. http://www.drugsandalcohol.ie/19628/ 
3. Department of Health (2012) Steering group report on a 
national substance misuse strategy Dublin: Department of 
Health. http://www.drugsandalcohol.ie/16908/ 
4. Department of Community, Rural and Gaeltacht Affairs 
(2009) National Drugs Strategy (interim) 2009–2016 Dublin: 
Department of Community, Rural and Gaeltacht Affairs. http://
www.drugsandalcohol.ie/12388/ 
5. Working Group on Drugs Rehabilitation (2007) National drugs 
strategy 2001–2008: rehabilitation. Report of the Working 
Group on Drugs Rehabilitation, May 2007 Dublin: Department 
of Community, Rural and Gaeltacht Affairs. http://www.
drugsandalcohol.ie/6267/ 
6. Expert Group on Mental Health Policy (2006) A vision for 
change: report of the Expert Group on Mental Health Policy 
Dublin: Stationery Office. http://www.drugsandalcohol.ie/6154/ 
Community-based responses
Actions to strengthen community-based responses include 
(p. 59): 
• development and distribution of standardised problem 
alcohol and substance use screening and brief 
intervention SAOR (Support, Ask and Assess, Offer 
Assistance and Refer) toolkits to support Tier 1 and 
Tier 2 services, and 
• publication of a Guiding Framework for Education and 
Training in Screening and Brief Intervention for Problem 
Alcohol Use for nurses and midwives in acute, primary 
and community settings.
The aim is to roll out SAOR screening and brief intervention 
training to 300 staff for problem alcohol and substance 
use within Tier 1 and Tier 2 services, and to deliver 30 
SAOR trainings and complete four train-the-trainer 
programmes nationally.
To strengthen community development approaches in 
line with the Healthy Ireland framework, Social Inclusion 
Services are also to establish a social inclusion working 
group on community development, to incorporate principles 
in respect of addressing health inequalities, community 
development, community participation, social prescribing 
etc. with a focus on vulnerable communities (p. 59). 
mental health
The mental health service, integrated with other areas of 
the wider health service, extends from promoting positive 
mental health and suicide prevention through to supporting 
those experiencing severe and disabling mental illness. It 
includes specialised secondary care services for children 
and adolescents, adults, older persons and those with 
an intellectual disability and a mental illness. The 10-year 
national policy, A Vision for Change,6 continues to inform 
the roadmap, charting the way forward for the mental 
health service. 
the service plan is designed to place people at 
the centre of the services we provide and to help 
improve the overall health of the population, no 
matter where people live, what stage of life they 
are at, or what their healthcare needs may be.
hSe national service plan continued
28
dr
ug
ne
t I
R
EL
AN
D
   
   
Is
su
e 
57
 |  
Sp
ri
ng
 2
0
16
Table 1: Tusla’s corporate targets for 2017 – progress in 2015 and priorities for 20163 
 Output targets, 2017 Progress in 2015 Priorities in 2016
A. Tusla’s child protection 
processes and systems are 
responding to children at risk 
in a timely fashion
• Child Protection Notification System 
(CPNS) available to external services
• National Out-of-Hours Service is 
operational
• Integrated performance reports being 
published quarterly on web site
• Early-warning Need-to-Know system 
refined and agreed with Department 
of Children & Youth Affairs
• Ahead of commencement and 
implementation of revised 
Children First guidelines, a National 
Implementation Team will be ensuring 
readiness for mandated reporting 
systems and responses, by preparing 
information and guidance for those 
carrying out this work, training 
and e-learning, and a full range of 
information and advice.
• Revision of national after-care policy 
and preparation of new statutory 
provisions to ensure all eligible young 
people have a statutory right to an 
aftercare plan.
• Ahead of Adoption (Information and 
Tracing) Bill, three working groups 
will ensure full public awareness, 
assessment of compelling reasons 
and establishment of adoption 
information register.
• A plan will be developed to tackle 
resource deficits, e.g. unallocated 
cases, and time lags between 
referrals and assessments.
• National Incident Management System 
(NIMS) will be rolled out.
• Quality Assurance directorate will 
ensure full implementation of Tell 
Us at Tusla and the NIMS complaints 
module.
B. All services, processes and 
systems underpinning children 
and family policy are 
evidence-informed.
• National Policy catalogue developed 
and accessible by all Tusla staff
• Draft Quality Assurance Framework 
developed 
• Research strategy approved and 
national operating model agreed
• Policy development will become 
standardised through establishment 
of National Policy Oversight Group.
• Child Protection and Welfare 
Handbook will be reviewed.
• Family Support Services will 
be further developed through 
recruitment, training and 
implementation of an audit tool for 
family support.
• A Research Ethics Committee will 
be established and a research needs 
analysis completed.
• Draft Quality Assurance Framework 
will be piloted in Q1.
tusla priorities for 2016
On 10 December 2015 Gordon Jeyes, the Chief Executive of TUSLA, the Child and Family 
Agency, appeared before the Joint Oireachtas Committee on Health and Children1 to give an 
update on TUSLA’s activities in 2015 and its priorities for 2016 (Table 1). The update reported 
progress in implementing TUSLA’s first corporate plan, which was launched in February 2015.2
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Table 1: Tusla’s corporate targets for 2017 – progress in 2015 and priorities for 20163 
 Output targets, 2017 Progress in 2015 Priorities in 2016
C. Provision of a targeted range of 
family-orientated supports
• Resourcing framework for supporting 
parents agreed, co-ordinators in 
place and support materials launched
• Alternative care strategy is being 
refined
• Shifting from a grants system to a 
commissioning strategy
• System in place for national oversight 
of all services relating to domestic, 
sexual and gender-based violence 
(DSGV)
• Family Resource Centres now a 
recognised participant in service 
delivery framework
• Through Children and Young People 
Services Committee, local needs and 
priorities will inform the allocation of 
funding.
• Children in Care multi-disciplinary 
teams will be expanded to provide for 
four regional teams with enhanced 
capacity to support children in care 
with challenging behaviour.
• An Alternative Care Strategy will be 
developed, including new metrics, 
and a Children in Care to Adoption 
Handbook will be developed.
• A Commissioning Support Unit and 
annual commissioning cycle will be 
developed.
• DSGV services – governance and 
oversight with standard reporting 
framework for services will be 
implemented, and information 
capability to support delivery of 
services will be developed.
D. Attendance, participation and 
retention in full-time education 
is embedded in service delivery.
• Integrated service management 
structure approved and national lead 
managers being appointed
• School Completion Programme (SCP) 
reviewed 
• Early-years inspection registration 
managers are in place and national 
governance structure established
• The community strengths of the SCP 
will be built on, and an integrated 
approach to educational welfare, 
home school liaison and school 
completion will be pursued.
• Early Years Inspectorate will develop 
and implement new processes and 
systems in respect of new regulations.
• A Central Registration Office will 
be established and an ICT system 
developed to support intelligence-
driven inspections.
• A review of Section 14 assessments 
for those educated at places other 
than school will be completed.
• Participation and achievement in 
education of all children in care will 
be the focus of specific monitoring.
Brigid Pike
1. Joint Oireachtas Committee on Health and Children (2015, 10 December) Update on Child and Family Services: Tusla. Retrieved 
27 January 2016 http://oireachtasdebates.oireachtas.ie/debates%20authoring/debateswebpack.nsf/committeetakes/
HEJ2015121000002?opendocument#C00100 
2. Tusla – Child and Family Agency (2014) Corporate plan 2015 –2017 Dublin: Tusla. http://www.drugsandalcohol.ie/23497/ 
See also B Pike (2015) Tusla publishes first corporate plan Drugnet Ireland (54): 22–23 http://www.drugsandalcohol.ie/24236/ 
3. Jeyes G (2015, 10 December) Opening statement to Joint Committee on Health and Children. Retrieved 27 January 2016 
http://www.tusla.ie/news/opening-statement-to-joint-committee-on-health-and-children
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UPDATES
Recent 
publications
The following abstracts are cited 
from recently published journal articles 
relating to the drugs situation in Ireland.
Changes in psychological well-being 
among heroin-dependent adolescents 
during psychologically supported 
opiate substitution treatment
Smyth BP, Ducray K and Cullen W (2016) 
Early Intervention in Psychiatry,  
Early online.  
http://www.drugsandalcohol.ie/25117/ 
Heroin-dependent adolescents 
demonstrate high rates of comorbid 
psychological problems. Among heroin-
dependent adults, opiate substitution 
treatment (OST) programmes appear 
to reduce mental health problems. We 
sought to examine the impact of OST on 
psychological well-being in adolescents, 
as this is unknown. We conducted a 
prospective study examining psychological 
well-being in heroin dependent 
adolescents, aged 18 years or younger, 
engaged in outpatient psychologically 
supported OST. Patients were treated 
with either methadone or buprenorphine. 
This was complemented with individual 
key working, counselling (motivational 
interviewing and cognitive behavioral 
therapy) and group work focusing on life 
skills. The Beck Youth Inventory was used 
to measure psychological well-being at 
treatment entry and repeated after 4 
months of treatment.
Among 55 consecutive treatment 
episodes, we examined the 32 episodes 
where the patient persisted with the OST 
programme. Polysubstance use was the 
norm at treatment entry. At follow-up, 
the median doses of methadone and 
buprenorphine were 50 mg and 8 mg, 
respectively. Only three patients were 
treated with antidepressant medication. 
There was significant improvement in the 
mean depression (65.0 to 57.9, P = 0.001), 
anxiety (61.7 to 57.0, P = 0.006) and 
anger (57.8 to 54.6, P = 0.009) subscale 
scores. The self-concept and disruptive 
behaviour subscale scores did not 
improve significantly. In this relatively 
short-term follow-up, psychosocially 
assisted OST appears to be associated 
with improved psychological well-being 
in heroin-dependent adolescents, 
especially in the area of depressive and 
anxiety symptoms.
the injecting use of image and 
performance-enhancing drugs 
(IPED) in the general population: 
a systematic review
Brennan R, Wells JSG and Van Hout MC 
(2016) Health and Social Care in the 
Community, Early online. 
http://www.drugsandalcohol.ie/25116/ 
Injecting use of image and 
performance-enhancing drugs (IPED) 
in the general population is a public 
health concern. A wide and varied 
range of IPED are now easily accessible 
to all through the online market. A 
comprehensive literature review was 
undertaken according to Critical 
Appraisal Skills Programme (CASP) 
guidelines for systematic review, to 
identify the relevant literature. No 
date restrictions were placed on the 
database search in the case of human 
growth hormone melanotan I and 
II, and oil and cosmetic injectables. 
In the case of anabolic androgenic 
steroids search dates were restricted 
to January 2014–2015. Publications not 
in English and with a lack of specificity 
to the topic were excluded. The review 
yielded 133 relevant quantitative and 
qualitative papers, clinical trials, clinical 
case presentations and editorials/
reports. Findings were examined/
reviewed under emergent themes 
which identified/measured extent of 
use, user profiling, sourcing, product 
endorsement, risk behaviours and 
health outcomes in users. Motivation 
for IPED use may be grounded in 
appearance, pursuit of health and 
youth, and body image disturbance. 
IPED users can practice moderated 
use, with pathological use linked to 
high-risk behaviours, which may be 
normalised within IPED communities. 
Many IPED trajectories and pathways of 
use are not scientifically documented. 
Much of this information may be 
available online in IPED specific 
discussion forums, an underutilised 
setting for research, where uncensored 
discourse takes place among users. 
This review underscores the need for 
future internet and clinical research 
to investigate prevalence and patterns 
of injecting use, and to map health 
outcomes in IPED users. This paper 
provides community-based clinical 
practice and health promotion services 
with a detailed examination and 
analysis of the injecting use of IPED, 
highlighting the patterns of this public 
health issue. It serves to disseminate 
updated publication information 
to health and social policy makers 
and those in health service practice 
who are involved in harm reduction 
intervention.
Seventeen year mortality in a cohort 
of patients attending opioid agonist 
treatment in Ireland 
Klimas J, Keane A, Cullen W, O’Kelly F and 
Bury G (2016) The European Journal of 
General Practice, Early online. pp. 1–2 
http://www.drugsandalcohol.ie/24856/ 
Commentary on ‘Methadone-
maintained patients in primary care 
have higher rates of chronic disease’ 
by O’Toole et al., European Journal of 
General Practice 2014 (20): 275–80
over-the-counter codeine – from 
therapeutic use to dependence, and 
the grey areas in between
Clyne B, Nielsen S and Van Hout MC 
(2016) Current Topics in Behavioral 
Neurosciences, Early online
http://www.drugsandalcohol.ie/25048/ 
Codeine is a widely used analgesic, 
that is available for sale in pharmacies 
over the counter (OTC) in a number 
of countries including the UK, South 
Africa, Ireland, France and Australia. In 
these countries with OTC codeine sales 
there have been emerging concerns 
about misuse of and dependence 
on codeine containing combination 
analgesics, with increasing numbers 
of people presenting for help with 
codeine dependence at primary care 
and addiction treatment services. This 
has led to many countries to review 
availability of codeine in OTC available 
preparations, and to consider possible 
measures to reduce harms from misuse 
of OTC codeine containing combination 
analgesics.
Injection of new psychoactive 
substance snow blow associated 
with recently acquired hIv 
infections among homeless 
people who inject drugs in Dublin, 
Ireland, 2015
Giese C et al. (2015) Euro surveillance: 
bulletin Européen sur les maladies 
transmissibles [European communicable 
disease bulletin] 20 (40)
 http://www.drugsandalcohol.ie/ 25015/
In February 2015, an outbreak of 
recently acquired HIV infections among 
people who inject drugs (PWID) was 
identified in Dublin, following similar 
outbreaks in Greece and Romania 
in 2011. We compared drug and risk 
behaviours among 15 HIV cases and 
39 controls. Injecting a synthetic 
cathinone, snow blow, was associated 
with recent HIV infection (AOR: 49; 
p = 0.003). Prevention and control 
efforts are under way among PWID 
in Dublin, but may also be needed 
elsewhere in Europe.
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Case-control study of risks and 
causes of death amongst opioid 
dependent patients on methadone 
maintenance treatment 
Truszkowska E, McCarron P, Konovalov 
P, Galander T, Lyons S, Keenan E and 
Smyth BP (2015) The Canadian Journal of 
Addiction 6 (3): 17–26
http://www.drugsandalcohol.ie/25004 
This article is discussed in detail on 
pages 5 and 6 of this issue.
Personality and substance use: 
psychometric evaluation and 
validation of the Substance Use 
Risk Profile Scale (SURPS) in 
English, Irish, French, and 
German adolescents
Jurk S et al. (2015) Alcoholism Clinical 
and Experimental Research 39 (11): 
2234–2248
http://www.drugsandalcohol.ie/25004/
The aim of this present longitudinal 
study was the psychometric evaluation 
of the Substance Use Risk Profile 
Scale (SURPS). The authors analyzed 
data from N=2,022 adolescents 
aged 13 to 15 at baseline assessment 
and 2 years later (mean interval 2.11 
years). Missing data at follow-up 
were imputed (N=522). Psychometric 
properties of the SURPS were 
analyzed using confirmatory factor 
analysis. We examined structural as 
well as convergent validity with other 
personality measurements and drinking 
motives, and predictive validity for 
substance use at follow-up.
The hypothesized 4-factorial structure 
(i.e. anxiety sensitivity, hopelessness, 
impulsivity [IMP], and sensation seeking 
[SS]) based on all 23 items resulted 
in acceptable fit to empirical data, 
acceptable internal consistencies, 
low to moderate test-retest reliability 
coefficients, as well as evidence for 
factorial and convergent validity. The 
proposed factor structure was stable 
for both males and females and, 
to lesser degree, across languages. 
However, only the SS and the IMP 
subscales of the SURPS predicted 
substance use outcomes at 16 years 
of age.
The SURPS is unique in its specific 
assessment of traits related to 
substance use disorders as well as the 
resulting shortened administration 
time. Test-retest reliability was low to 
moderate and comparable to other 
personality scales. However, its relation 
to future substance use was limited to 
the SS and IMP subscales, which may be 
due to the relatively low-risk substance 
use pattern in the present sample.
vulnerable families and drug use: 
examining care admissions of 
children of parents attending an 
Irish drug treatment facility 
McGivern A and McDonnell C (2015) The 
Irish Social Worker (Spring): 17–23 
http://www.drugsandalcohol.ie/24712/
Harmful substance use has a 
detrimental effect on parenting, and 
child welfare agencies consistently 
confirm such usage as a primary factor 
in initial referral. This article examines 
the circumstances of child admissions 
to care over a nine year period, from 
families where one or both parents 
attend a centralized drug treatment 
services. A recurrent theme during the 
study period was low rates of family 
reunifications within a twelve month 
period. Furthermore, we identified 
factors which in the view of natural 
parents and the service social work 
team have contributed significantly 
when families have been reunited.
low resolution and high resolution 
mS for studies on the metabolism 
and toxicological detection of 
the new psychoactive substance 
methoxypiperamide (meoP)
Meyer MR, Holderbaum A, Kavanagh P 
and Maurer HH (2015) Journal of Mass 
Spectrometry 50 (10): 1163–74
http://www.drugsandalcohol.ie/24617/
In 2013, the new psychoactive substance 
methoxypiperamide (MeOP) was first 
reported to the European Monitoring 
Centre for Drugs and Drug Addiction. Its 
structural similarity to already controlled 
piperazine designer drugs might have 
contributed to the decision to offer 
MeOP for online purchase. 
The aims of this work were to identify 
the phase I/II metabolites of MeOP in 
rat urine and the human cytochrome 
P450 (CYP) isoenzymes responsible 
for the initial metabolic steps. 
Finally, the detectability of MeOP in 
rat urine by gas chromatography-
mass spectrometry (GC-MS) and 
liquid chromatography coupled with 
multistage mass spectrometry (LC-MS(n) 
) standard urine screening approaches 
(SUSAs) was evaluated. After sample 
preparation by cleavage of conjugates 
followed by extraction for elucidating 
phase I metabolites, the analytes were 
separated and identified by GC-MS 
as well as liquid chromatography-high 
resolution-tandem mass spectrometry 
(LC-HR-MS/MS). For detection of 
phase II metabolites, the analytes were 
separated and identified after urine 
precipitation followed by LC-HR-MS/
MS. The following metabolic steps 
could be postulated: hydrolysis of the 
amide, N-oxide formation, N- and/
or O-demethylation, oxidation of the 
piperazine ring to the corresponding 
keto-piperazine, piperazine ring 
opening followed by oxidation of a 
methylene group to the corresponding 
imide, and hydroxylation of the phenyl 
group. Furthermore, N-acetylation, 
glucuronidation and sulfation 
were observed. 
Using human CYPs, CYP1A2, CYP2C19, 
CYP2D6, and/or CYP3A4 were found 
to catalyze N-oxide formation and N-, 
O-demethylation and/or oxidation. 
Mostly MeOP and N-oxide-MeOP but to 
a minor degree also other metabolites 
could be detected in the GC-MS and 
LC-MS(n) SUSAs. 
Examining the use of community 
service orders as alternatives to 
short prison sentences in Ireland 
O’Hara K and Rogan M (2015) Irish 
Probation Journal, 12, October 2015 
http://www.drugsandalcohol.ie/24883/
Ireland’s highly discretionary sentencing 
system provides a rare opportunity to 
study the behaviour of judges when 
relatively free of externally imposed 
constraints. While this is so, few 
studies have investigated sentencing 
trends. In 2011, Ireland introduced the 
Criminal Justice (Community Service) 
(Amendment) Act 2011 requiring courts 
to consider imposing Community Service 
Orders (CSOs) in cases where sentences 
of less than twelve months are deemed 
appropriate. A CSO is a direct prison 
alternative requiring offenders to 
complete between forty and 240 
hours unpaid community work in lieu 
of a prison term. In order to complete 
comparative analysis, administrative 
data pertaining to all cases sentenced 
to a short term of imprisonment or CSO 
between 2011 and 2012 were linked and 
analysed. Analysis of offence groups 
showed that more cases convicted 
of drug, public order, and robbery or 
related offences received Community 
Service than was expected; however 
effect sizes were small. Findings showed 
the average number of Community 
Service hours equivalent to one month 
of imprisonment differed by offence 
type and District Court jurisdiction. As 
the first of its kind in Ireland, this study 
provides a rare glimpse of the use of 
these two alternative criminal justice 
sanctions. Findings and their implications 
are discussed.
Coolmine therapeutic Community, 
Dublin: a forty-year history of 
Ireland’s first voluntary drug 
treatment service
Butler S (2015) Addiction Early online 
http://www.drugsandalcohol.ie/24509/
To document the evolution over 
forty years (1973–2013) of Coolmine 
recent publications continued
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first voluntary drug treatment service) 
against a background of broader drug 
policy developments in the Republic 
of Ireland and elsewhere during this 
period, data were gathered by means 
of archival research within Coolmine, 
complemented by semi-structured 
interviews with former clients, current 
and former Coolmine management and 
staff, and representatives of outsider 
stakeholder interests.
Coolmine’s history has three phases: 
(1) an early and uncontentious phase 
in which external authorities provided 
financial support for Coolmine without 
questioning its work practices or 
outcomes; (2) a middle, controversial 
phase in which Coolmine struggled 
for survival in an external policy 
environment now dominated by harm 
reduction strategies; and (3) a final 
phase in which, through the use of 
conventional corporate governance, 
Coolmine management sought to repair 
its damaged reputation by introducing 
evidence-based clinical practices.
Coolmine Therapeutic Community 
was established when drug treatment 
services in Ireland were in their 
infancy, and its changing fortunes 
over subsequent decades reflected 
changing perceptions of what constitutes 
appropriate addiction treatment – and in 
particular the role to be played by former 
addicts within addiction treatment 
systems – as well as changing perceptions 
of funding relationships between 
statutory authorities and voluntary 
providers of health and social services.
the drug situation in Europe: 
an overview of data available on 
illicit drugs and new psychoactive 
substances from European 
monitoring in 2015
Mounteney J, Griffiths P, Sedefov R, Noor 
A, Vicente J and Simon R (2015) Addiction 
Early online 
http://www.drugsandalcohol.ie/24570/
A central task for the European 
Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is to produce 
an annual report of the latest data 
available on drug demand and 
drug supply in Europe. This paper 
is intended to facilitate a better 
understanding of, and easier access to, 
the main quantitative European level 
data sets available in 2015.
The European reporting system 
formally covers all 28 European Union 
(EU) Member States, Norway and 
Turkey and incorporates multiple 
indicators alongside an early warning 
system (EWS) on uncontrolled new 
psychoactive substances (NPS). While 
epidemiological information is based 
largely on registries, surveys and other 
routine data reported annually, the 
EWS collects case-based data on an 
ongoing basis. The 2015 reporting 
exercise is centred primarily on a set 
of standardized reporting tools.
The most recent data provided by 
European countries are presented, 
including data on drug use, drug-
related morbidity and mortality, 
treatment demand, drug markets 
and new psychoactive substances, 
with data tables provided and 
methodological information. A number 
of key results are highlighted for 
illustrative purposes. Drug prevalence 
estimates from national surveys 
since 2012 (last year prevalence 
of use among the 15–34 age band) 
range from 0.4% in Turkey to 22.1% 
in France for cannabis, from 0.2% in 
Greece and Romania to 4.2% in the 
United Kingdom for cocaine, from 
0.1% in Italy and Turkey to 3% in 
the Czech Republic and the United 
Kingdom for ecstasy, and from 0.1% 
or less in Romania, Italy and Portugal 
to 2.5% in Estonia for amphetamine. 
Declining trends in new HIV detections 
among people who inject drugs are 
illustrated, in addition to presentation 
of a breakdown of NPS reported to the 
EU early warning system, which have 
risen exponentially from fewer than 20 
a year between 2005 and 2008, to 101 
reported in 2014.
Structured information is now 
available on patterns and trends in 
drug consumption in Europe, which 
permits triangulation of data from 
different sources and consideration 
of methodological limitations. Opioid 
drugs continue to place a burden on 
the drug treatment system, although 
both new heroin entrants and injecting 
show declines. More than 450 new 
psychoactive substances are now 
monitored by the European early 
warning system with 31 new synthetic 
cathinones and 30 new synthetic 
cannabinoid receptor agonists notified 
in 2014.
Alcohol consumption and 
cardiovascular disease, cancer, 
injury, admission to hospital, and 
mortality: a prospective cohort study 
Smyth A et al. (2015) Lancet 386 
(10007):1945-1954
http://www.drugsandalcohol.ie/24524/ 
Alcohol consumption is proposed to 
be the third most important modifiable 
risk factor for death and disability. 
However, alcohol consumption has 
been associated with both benefits 
and harms, and previous studies were 
mostly done in high-income countries. 
We investigated associations between 
alcohol consumption and outcomes 
in a prospective cohort of countries 
at different economic levels in five 
continents. We identified sufficient 
commonalities to support global health 
strategies and national initiatives to 
reduce harmful alcohol use.
We included information from 
12 countries participating in the 
Prospective Urban Rural Epidemiological 
(PURE) study, a prospective cohort study 
of individuals aged 35–70 years. We used 
Cox proportional hazards regression 
to study associations with mortality 
(n=2,723), cardiovascular disease 
(n=2,742), myocardial infarction (n=979), 
stroke (n=817), alcohol-related cancer 
(n=764), injury (n=824), admission to 
hospital (n=8786), and for a composite 
of these outcomes (n=11,963).
We included 114,970 adults, of whom 
12,904 (11%) were from high-income 
countries (HICs), 24,408 (21%) were 
from upper-middle-income countries 
(UMICs), 48,845 (43%) were from lower-
middle-income countries (LMICs), and 
28,813 (25%) were from low-income 
countries (LICs). Median follow-up 
was 4.3 years (IQR 3·0–6·0). Current 
drinking was reported by 36,030 (31%) 
individuals, and was associated with 
reduced myocardial infarction (hazard 
ratio [HR] 0·76 [95% CI 0·63–0·93]), but 
increased alcohol-related cancers (HR 
1·51 [1·22–1·89]) and injury (HR 1·29 [1·04–
1·61]). High intake was associated with 
increased mortality (HR 1·31 [1·04–1·66]). 
Compared with never drinkers, we 
identified significantly reduced hazards 
for the composite outcome for current 
drinkers in HICs and UMICs (HR 0·84 
[0·77–0·92]), but not in LMICs and LICs, 
for which we identified no reductions 
in this outcome (HR 1·07 [0·95–1·21]; 
pinteraction<0·0001).
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